Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 4.6.1.2 - guanylate cyclase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Achondroplasia
Natriuretic Peptide Expression and Function in GH3 Somatolactotropes and Feline Somatotrope Pituitary Tumours.
Phosphatase inhibition by LB-100 enhances BMN-111 stimulation of bone growth.
Acidosis
Endothelin and nitric oxide mediate adaptation of the cortical collecting duct to metabolic acidosis.
Nitric oxide from perivascular nerves modulates cerebral arterial pH reactivity.
Acute Coronary Syndrome
Role of epicardial adipose tissue NPR-C in acute coronary syndrome.
Acute Kidney Injury
C-type natriuretic peptide ameliorates ischemia/reperfusion-induced acute kidney injury by inhibiting apoptosis and oxidative stress in rats.
Disruption of guanylyl cyclase-G protects against acute renal injury.
Investigation of the role of nitric oxide/soluble guanylyl cyclase pathway in ascorbic acid-mediated protection against acute kidney injury in rats.
L-arginine as a therapeutic tool in kidney disease.
Novel analog of atrial natriuretic peptide selective for receptor-A produces increased diuresis and natriuresis in rats.
Urodilatin, not nitroprusside, combined with dopamine reverses ischemic acute renal failure.
Acute Lung Injury
Atrial natriuretic peptide attenuates agonist-induced pulmonary edema in mice with targeted disruption of the gene for natriuretic peptide receptor-A.
Guanylyl Cyclase Activation Reverses Resistive Breathing-induced Lung Injury and Inflammation.
Response to inhaled nitric oxide (NO) is not associated with changes of plasma cGMP levels in patients with acute lung injury.
The Role of Soluble Guanylyl Cyclase in Chronic Obstructive Pulmonary Disease.
Adenocarcinoma
A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C.
Ectopic expression of guanylyl cyclase C in adenocarcinomas of the esophagus and stomach.
Guanylyl cyclase C is a marker of intestinal metaplasia, dysplasia, and adenocarcinoma of the gastrointestinal tract.
Heterogeneous localization of adenylate and guanylate cyclases in R3230AC rat mammary adenocarcinoma cells.
In vivo imaging of human colon cancer xenografts in immunodeficient mice using a guanylyl cyclase C--specific ligand.
Inhibition of growth and guanylate cyclase activity of an undifferentiated prostate adenocarcinoma by an extract of the balsam pear (Momordica charantia abbreviata).
Pathological staging and therapy of oesophageal and gastric cancer.
Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase C.
TAK-264 (MLN0264) in Previously Treated Asian Patients with Advanced Gastrointestinal Carcinoma Expressing Guanylyl Cyclase C: Results from an Open-label, Non-randomized Phase 1 Study.
Adenoma
Use of guanylyl cyclase C for detecting micrometastases in lymph nodes of patients with colon cancer.
Adrenal Gland Neoplasms
Guanyl cyclase activity in normal adrenals and a corticosterone producing adrenal cancer of the rat.
Adrenocortical Carcinoma
Adrenocorticotropin-dependent particulate guanylate cyclase in rat adrenal and adrenocortical carcinoma: comparison of its properties with soluble guanylate cyclase and its relationship with ACTH-induced steroidogenesis.
Characterization and regulation by protein kinase C of renal glomerular atrial natriuretic peptide receptor-coupled guanylate cyclase.
Characterization of atrial-natriuretic-factor-receptor-coupled membrane guanylate cyclase from rat and mouse testes.
Demonstration of ACTH-sensitive particulate guanylate cyclase in adrenocortical carcinoma.
Dual regulation of adenylate cyclase and guanylate cyclase: alpha 2-adrenergic signal transduction in adrenocortical carcinoma cells.
Inhibition of alpha 2-adrenergic receptor-mediated cyclic GMP formation by a phorbol ester, a protein kinase C activator.
Negative regulation of atrial natriuretic factor receptor coupled membrane guanylate cyclase by phorbol ester. Potential protein kinase C regulation of cyclic GMP signal in isolated adrenocortical carcinoma cells of rat.
Ubiquitous and bifunctional 180 kDa atrial natriuretic factor-dependent guanylate cyclase.
Albuminuria
Effects of the Soluble Guanylate Cyclase Stimulator Praliciguat in Diabetic Kidney Disease: A Randomized Placebo-Controlled Clinical Trial.
Alcohol-Related Disorders
Augmented Stress-Induced Alcohol Drinking and Withdrawal in Mice Lacking Functional Natriuretic Peptide-A Receptors.
Alopecia
Guanylate cyclase activity in male pattern baldness. Stimulating effect of 3-beta-androstanediol.
Alzheimer Disease
Post-Transcriptional Regulation of Soluble Guanylate Cyclase that Governs Neuropathic Pain in Alzheimer's Disease.
Reduced expression of NO-sensitive guanylyl cyclase in reactive astrocytes of Alzheimer disease, Creutzfeldt-Jakob disease, and multiple sclerosis brains.
Reduced nitric oxide responsive soluble guanylyl cyclase activity in the superior temporal cortex of patients with Alzheimer's disease.
Anaphylaxis
Methylene blue for clinical anaphylaxis treatment: a case report.
Anemia, Sickle Cell
Beneficial Effects of Soluble Guanylyl Cyclase Stimulation and Activation in Sickle Cell Disease Are Amplified by Hydroxyurea: In Vitro and In Vivo Studies.
Olinciguat, a stimulator of soluble guanylyl cyclase, attenuates inflammation, vaso-occlusion and nephropathy in mouse models of sickle cell disease.
Aortic Aneurysm
Alternative splicing impairs soluble guanylyl cyclase function in aortic aneurysm.
Arrhythmias, Cardiac
The Relationship between Estrogen and Nitric Oxide in the Prevention of Cardiac and Vascular Anomalies in the Developing Zebrafish (Danio Rerio).
Asthma
An inherent dysfunction in soluble guanylyl cyclase is present in the airway of severe asthmatics and is associated with aberrant redox enzyme expression and compromised NO-cGMP signaling.
Carnosine as a regulator of soluble guanylate cyclase.
Effect of inhaled atrial natriuretic peptide and a neutral endopeptidase inhibitor on histamine-induced bronchoconstriction.
From bedside to bench--meeting report of the 7th International Conference on cGMP "cGMP: generators, effectors and therapeutic implications" in Trier, Germany, from June 19th to 21st 2015.
Guanylyl Cyclase Activation Reverses Resistive Breathing-induced Lung Injury and Inflammation.
NO-sensitive guanylyl cyclase in the lung.
Response of lymphocyte guanyl cyclase to propranolol, noradrenaline, thymoxamine, and acetylcholine in extrinsic bronchial asthma.
Review - Nutraceuticals Can Target Asthmatic Bronchoconstriction: NADPH Oxidase-Dependent Oxidative Stress, RhoA and Calcium Dynamics.
Soluble guanylate cyclase as an alternative target for bronchodilator therapy in asthma.
Soluble guanylyl cyclase expression is reduced in allergic asthma.
Soluble guanylyl cyclase is reduced in airway smooth muscle cells from a murine model of allergic asthma.
The Role of Soluble Guanylyl Cyclase in Chronic Obstructive Pulmonary Disease.
Astrocytoma
Mechanism of potentiation of LY83583-induced growth inhibition by sodium nitroprusside in human brain tumor cells.
Methylene blue induces cytotoxicity in human brain tumor cells.
Substance-P receptors in human primary neoplasms: tumoral and vascular localization.
The effect of unsaturated fatty acids on sodium nitroprusside stimulation of guanylate cyclase in the human astrocytoma clone, D384, and the human neuroblastoma clone, NB1-G.
The generation of nitric oxide participates in gamma IFN-induced MHC class II antigen expression by cultured astrocytoma cells.
Ataxia
Involvement of the alpha4beta2 nicotinic receptor subtype in nicotine-induced attenuation of delta9-THC cerebellar ataxia: role of cerebellar nitric oxide.
Atherosclerosis
Activation of soluble guanylyl cyclase prevents foam cell formation and atherosclerosis.
Alteration of the soluble guanylate cyclase system in coronary arteries of high cholesterol diet-fed rabbits.
Characterization of the human alpha1 beta1 soluble guanylyl cyclase promoter: key role for NF-kappaB(p50) and CCAAT-binding factors in regulating expression of the nitric oxide receptor.
Cygnets: in vivo characterization of novel cGMP indicators and in vivo imaging of intracellular cGMP.
High-density lipoprotein antagonizes the inhibitory effects of oxidized low-density lipoprotein and lysolecithin on soluble guanylyl cyclase.
Long-lasting cyclic guanosine-3',5'-monophosphate accumulation in the medium of cultured smooth muscle cells from atherosclerotic rabbit aortas in response to exogenous or endogenous nitric oxide.
Role of sGC-dependent NO signalling and myocardial infarction risk.
Sick vessel syndrome: vascular changes in hypertension and atherosclerosis.
YC-1 reduces placental sFlt-1 and soluble endoglin production and decreases endothelial dysfunction: A possible therapeutic for preeclampsia.
Blindness
A nonsense mutation in the retinal specific guanylate cyclase gene is the cause of Leber congenital amaurosis in a large inbred kindred from Jordan.
A novel mutation in the GUCY2D gene responsible for an early onset severe RP different from the usual GUCY2D-LCA phenotype.
AAV-mediated gene therapy in the guanylate cyclase (RetGC1/RetGC2) double knockout mouse model of Leber congenital amaurosis.
Activation of retinal guanylyl cyclase RetGC1 by GCAP1: stoichiometry of binding and effect of new LCA-related mutations.
Bicarbonate and Ca(2+) Sensing Modulators Activate Photoreceptor ROS-GC1 Synergistically.
Complete abolition of the retinal-specific guanylyl cyclase (retGC-1) catalytic ability consistently leads to leber congenital amaurosis (LCA).
Determining consequences of retinal membrane guanylyl cyclase (RetGC1) deficiency in human Leber congenital amaurosis en route to therapy: residual cone-photoreceptor vision correlates with biochemical properties of the mutants.
Different functional outcome of RetGC1 and RPE65 gene mutations in Leber congenital amaurosis.
Dimerization Domain of Retinal Membrane Guanylyl Cyclase 1 (RetGC1) Is an Essential Part of Guanylyl Cyclase-activating Protein (GCAP) Binding Interface.
Evaluating the Role of Retinal Membrane Guanylyl Cyclase 1 (RetGC1) Domains in Binding Guanylyl Cyclase-activating Proteins (GCAPs).
Evidence of a founder effect for the RETGC1 (GUCY2D) 2943DelG mutation in Leber congenital amaurosis pedigrees of Finnish origin.
Experimental Approaches for Defining the Role of the Ca
Factors that affect regulation of cGMP synthesis in vertebrate photoreceptors and their genetic link to human retinal degeneration.
First 3D-Structural Data of Full-Length Guanylyl Cyclase 1 in Rod-Outer-Segment Preparations of Bovine Retina by Cross-Linking/Mass Spectrometry.
Functional analyses of mutant recessive GUCY2D alleles identified in Leber congenital amaurosis patients: protein domain comparisons and dominant negative effects.
Functional consequences of a rod outer segment membrane guanylate cyclase (ROS-GC1) gene mutation linked with Leber's congenital amaurosis.
Genetic analysis of the guanylate cyclase activator 1B (GUCA1B) gene in patients with autosomal dominant retinal dystrophies.
GUCY2D mutations in retinal guanylyl cyclase 1 provide biochemical reasons for dominant cone-rod dystrophy but not for stationary night blindness.
Insights gained from gene therapy in animal models of retGC1 deficiency.
Insights into the role of RD3 in guanylate cyclase trafficking, photoreceptor degeneration, and Leber congenital amaurosis.
Lentiviral expression of retinal guanylate cyclase-1 (RetGC1) restores vision in an avian model of childhood blindness.
Mutations in the retinal guanylate cyclase (RETGC-1) gene in dominant cone-rod dystrophy.
Photoreceptor Guanylate Cyclase (GUCY2D) Mutations Cause Retinal Dystrophies by Severe Malfunction of Ca2+-Dependent Cyclic GMP Synthesis.
RD3 gene delivery restores guanylate cyclase localization and rescues photoreceptors in the Rd3 mouse model of Leber congenital amaurosis 12.
RD3, the protein associated with Leber congenital amaurosis type 12, is required for guanylate cyclase trafficking in photoreceptor cells.
Regulation of cGMP synthesis in photoreceptors: role in signal transduction and congenital diseases of the retina.
Regulation of retinal membrane guanylyl cyclase (RetGC) by negative calcium feedback and RD3 protein.
Retinal diseases linked with photoreceptor guanylate cyclase.
Retinal guanylyl cyclase activation by calcium sensor proteins mediates photoreceptor degeneration in an rd3 mouse model of congenital human blindness.
Retinal-specific guanylate cyclase gene mutations in Leber's congenital amaurosis.
Spectrum of retGC1 mutations in Leber's congenital amaurosis.
The R838S Mutation in Retinal Guanylyl Cyclase 1 (RetGC1) Alters Calcium Sensitivity of cGMP Synthesis in the Retina and Causes Blindness in Transgenic Mice.
Two clusters of surface-exposed amino acid residues enable high-affinity binding of retinal degeneration-3 (RD3) protein to retinal guanylyl cyclase.
Variants at codon 838 in the GUCY2D gene result in different phenotypes of cone rod dystrophy.
Bone Resorption
C-type natriuretic peptide increases bone resorption in 1,25-dihydroxyvitamin D3-stimulated mouse bone marrow cultures.
Oral administration of soluble guanylate cyclase agonists to rats results in osteoclastic bone resorption and remodeling with new bone formation in the appendicular and axial skeleton.
Bradycardia
Nitric oxide in the insular cortex modulates baroreflex responses in a cGMP-independent pathway.
Brain Diseases
Pharmacological manipulation of cGMP and NO/cGMP in CNS drug discovery.
Brain Edema
Nitric Oxide/Cyclic Guanosine Monophosphate Signaling via Guanylyl Cyclase Isoform 1 Mediates Early Changes in Synaptic Transmission and Brain Edema Formation after Traumatic Brain Injury.
Brain Injuries
Nitric Oxide/Cyclic Guanosine Monophosphate Signaling via Guanylyl Cyclase Isoform 1 Mediates Early Changes in Synaptic Transmission and Brain Edema Formation after Traumatic Brain Injury.
Brain Injuries, Traumatic
Nitric Oxide/Cyclic Guanosine Monophosphate Signaling via Guanylyl Cyclase Isoform 1 Mediates Early Changes in Synaptic Transmission and Brain Edema Formation after Traumatic Brain Injury.
Brain Ischemia
Nitric oxide production during focal cerebral ischemia in rats.
Brain Neoplasms
Guanylate cyclase in human brain tumors: regulation of cellular growth.
Mechanism of potentiation of LY83583-induced growth inhibition by sodium nitroprusside in human brain tumor cells.
Regulation of blood-brain tumor barrier permeability by calcium-activated potassium channels.
Regulation of the cyclic guanosine 3'-5' monophosphate system in human brain tumors.
Breast Neoplasms
Differential expression of alternative transcripts of soluble guanylyl cyclase, GYCY1a3 and GUCY1b3 genes, in the malignant and benign breast tumors.
EGCG inhibits mammary cancer cell migration through inhibition of nitric oxide synthase and guanylate cyclase.
Elevation of soluble guanylate cyclase suppresses proliferation and survival of human breast cancer cells.
Epigenetic regulation of soluble guanylate cyclase (sGC) ?1 in breast cancer cells.
Soluble guanylate cyclase isoenzymes: The expression of ?1, ?2, ?1, and ?2 subunits in the benign and malignant breast tumors.
Bronchial Hyperreactivity
Inhibition of guanylyl cyclase in the airways hyperreactivity.
CADASIL
Peripheral arteriopathy caused by Notch3 gain-of-function mutation involves ER and oxidative stress and blunting of NO/sGC/cGMP pathway.
Carcinogenesis
Bioactivity of Oral Linaclotide in Human Colorectum for Cancer Chemoprevention.
Colorectal cancer is a paracrine deficiency syndrome amenable to oral hormone replacement therapy.
Corruption of homeostatic mechanisms in the guanylyl cyclase C signaling pathway underlying colorectal tumorigenesis.
Development and molecular characterization of HCT-116 cell lines resistant to the tumor promoter and multiple stress-inducer, deoxycholate.
Ectopic expression of guanylyl cyclase C and endogenous ligand guanylin correlates significantly with Helicobacter pylori infection in gastric carcinogenesis.
Guanylyl cyclase C as a biomarker for immunotherapies for the treatment of gastrointestinal malignancies.
Guanylyl cyclase C suppresses intestinal tumorigenesis by restricting proliferation and maintaining genomic integrity.
Hydrazine activation of guanylate cyclase: potential application to tobacco carcinogenesis.
Lineage-specific T-cell responses to cancer mucosa antigen oppose systemic metastases without mucosal inflammatory disease.
Loss of guanylyl cyclase C (GCC) signaling leads to dysfunctional intestinal barrier.
Modulation of rat guanylate cyclase activity in vitro by chemical carcinogens.
Natriuretic peptide receptor A as a novel target for cancer.
Saccharin inhibits guanylate cyclase activity: possible relationship to carcinogenesis.
Silencing the intestinal GUCY2C tumor suppressor axis requires APC loss of heterozygosity.
[Disordered regulation of cell membrane adenyl cyclase and guanyl cyclase activity as a possible factor in carcinogenesis]
Carcinoma
An oxidized analog of alpha-human atrial natriuretic polypeptide is a selective agonist for the atrial-natriuretic-polypeptide clearance receptor which lacks a guanylate cyclase.
Characterization of the synergistic interaction of Escherichia coli heat-stable toxin and carbachol.
Combined application of camptothecin and the guanylate cyclase activator YC-1: Impact on cell death and apoptosis-related proteins in ovarian carcinoma cell lines.
Decreased luteinizing hormone receptor mRNA expression in human ovarian epithelial cancer.
Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma.
Effects of marine sponge extracts on mitogen-activated protein kinase (MAPK/ERK(1,2)) activity in SW-13 human adrenal carcinoma cells.
Expression of iNOS--a favourable prognostic marker for early-stage carcinoma of the uterine cervix.
GCAP-II: isolation and characterization of the circulating form of human uroguanylin.
Guanylate Cyclase Activator YC-1 Enhances TRAIL-Induced Apoptosis in Human Epithelial Ovarian Carcinoma Cells via Activation of Apoptosis-Related Proteins.
Guanylate cyclase activator YC-1 potentiates apoptotic effect of licochalcone A on human epithelial ovarian carcinoma cells via activation of death receptor and mitochondrial pathways.
Guanylate cyclase activity in normal and neoplastic squamous epithelia from the upper aero-digestive tract.
Guanylyl cyclase C agonists regulate progression through the cell cycle of human colon carcinoma cells.
Guanylyl cyclase C is a selective marker for metastatic colorectal tumors in human extraintestinal tissues.
Interaction of guanylyl cyclase C with SH3 domain of Src tyrosine kinase. Yet another mechanism for desensitization.
Internalization of E. coli ST mediated by guanylyl cyclase C in T84 human colon carcinoma cells.
Involvement of protein kinase C in the mechanism of action of Escherichia coli heat-stable enterotoxin (STa) in a human colonic carcinoma cell line, COLO-205.
Ligand-based histochemical localization and capture of cells expressing heat-stable enterotoxin receptors.
Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit.
Negative regulation of atrial natriuretic factor receptor coupled membrane guanylate cyclase by phorbol ester. Potential protein kinase C regulation of cyclic GMP signal in isolated adrenocortical carcinoma cells of rat.
Nitric oxide pathways in human bladder carcinoma. The distribution of nitric oxide synthases, soluble guanylyl cyclase, cyclic guanosine monophosphate, and nitrotyrosine.
Proliferative signaling by store-operated calcium channels opposes colon cancer cell cytostasis induced by bacterial enterotoxins.
Soluble guanylate cyclase stimulators increase sensitivity to cisplatin in head and neck squamous cell carcinoma cells.
Substance-P receptors in human primary neoplasms: tumoral and vascular localization.
TAK-264 (MLN0264) in Previously Treated Asian Patients with Advanced Gastrointestinal Carcinoma Expressing Guanylyl Cyclase C: Results from an Open-label, Non-randomized Phase 1 Study.
The beta(2) subunit of soluble guanylyl cyclase contains a human-specific frameshift and is expressed in gastric carcinoma.
The Escherichia coli heat-stable enterotoxin is a long-lived superagonist of guanylin.
Use of guanylyl cyclase C for detecting micrometastases in lymph nodes of patients with colon cancer.
Carcinoma, Hepatocellular
Guanyl cyclase activity in Morris hepatomas. 7787, 7795, 7800 and 9618A-2.
Increased guanylate cyclase activity and guanosine 3',5'-monophosphate content in ethionine-induced hepatomas.
Increased particulate and decreased soluble guanylate cyclase activity in regenerating liver, fetal liver, and hepatoma.
Pancreastatin, a chromogranin A-derived peptide, inhibits DNA and protein synthesis by producing nitric oxide in HTC rat hepatoma cells.
Properties of guanylate cyclase in adult rat liver and several Morris hepatomas.
[Concentration of cyclic nucleotides, activity of adenylate cyclase, 3',5'-AMP phosphodiesterase and guanylate cyclase in plasma membranes from liver and hepatomas of different degrees of malignancy]
Carcinoma, Medullary
Expression of the intestinal biomarkers Guanylyl cyclase C and CDX2 in poorly differentiated colorectal carcinomas.
Carcinoma, Non-Small-Cell Lung
Inhibition of non-small cell lung cancer cell migration by grape seed proanthocyanidins is mediated through the inhibition of nitric oxide, guanylate cyclase, and ERK1/2.
Substance-P receptors in human primary neoplasms: tumoral and vascular localization.
Carcinoma, Ovarian Epithelial
Guanylate Cyclase Activator YC-1 Enhances TRAIL-Induced Apoptosis in Human Epithelial Ovarian Carcinoma Cells via Activation of Apoptosis-Related Proteins.
Guanylate cyclase activator YC-1 potentiates apoptotic effect of licochalcone A on human epithelial ovarian carcinoma cells via activation of death receptor and mitochondrial pathways.
Carcinoma, Squamous Cell
Guanylate cyclase activity in normal and neoplastic squamous epithelia from the upper aero-digestive tract.
Soluble guanylate cyclase stimulators increase sensitivity to cisplatin in head and neck squamous cell carcinoma cells.
Cardio-Renal Syndrome
Soluble guanylate cyclase: a potential therapeutic target for heart failure.
Cardiomegaly
Androgen contributes to gender-related cardiac hypertrophy and fibrosis in mice lacking the gene encoding guanylyl cyclase-A.
Angiotensin II-induced ventricular hypertrophy and extracellular signal-regulated kinase activation are suppressed in mice overexpressing brain natriuretic peptide in circulation.
C-type natriuretic peptide: A new cardiac mediator.
Calcineurin-nuclear factor of activated T cells pathway-dependent cardiac remodeling in mice deficient in guanylyl cyclase A, a receptor for atrial and brain natriuretic peptides.
CaMKII-mediated increased lusitropic responses to beta-adrenoreceptor stimulation in ANP-receptor deficient mice.
Cinaciguat prevents the development of pathologic hypertrophy in a rat model of left ventricular pressure overload.
Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection.
Differential regulation of membrane guanylyl cyclases in congestive heart failure: natriuretic peptide receptor (NPR)-B, Not NPR-A, is the predominant natriuretic peptide receptor in the failing heart.
Exposure to cigarette smoke abrogates the beneficial effect of ischemic postconditioning.
Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension.
Expression of constitutively active guanylate cyclase in cardiomyocytes inhibits the hypertrophic effects of isoproterenol and aortic constriction on mouse hearts.
KMUP-1 inhibits hypertension-induced left ventricular hypertrophy through regulation of nitric oxide synthases, ERK1/2, and calcineurin.
Left but not right cardiac hypertrophy in atrial natriuretic peptide receptor-deficient mice is prevented by angiotensin type 1 receptor antagonist losartan.
Liraglutide prevents and reverses monocrotaline-induced pulmonary arterial hypertension by suppressing ET-1 and enhancing eNOS/sGC/PKG pathways.
Magnetic resonance imaging accurately estimates LV mass in a transgenic mouse model of cardiac hypertrophy.
Novel insights into the mechanisms mediating the local antihypertrophic effects of cardiac atrial natriuretic peptide: role of cGMP-dependent protein kinase and RGS2.
Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A.
Regulator of G-protein signaling subtype 4 mediates antihypertrophic effect of locally secreted natriuretic peptides in the heart.
Renal hyporesponsiveness to atrial natriuretic peptide in congestive heart failure results from reduced atrial natriuretic peptide receptor concentrations.
Role of natriuretic peptide receptor guanylyl cyclase-A in myocardial infarction evaluated using genetically engineered mice.
The soluble guanylyl cyclase activator bay 58-2667 selectively limits cardiomyocyte hypertrophy.
The specific mineralocorticoid receptor blocker eplerenone attenuates left ventricular remodeling in mice lacking the gene encoding guanylyl cyclase-A.
Ventricular arrhythmias, increased cardiac calmodulin kinase II expression, and altered repolarization kinetics in ANP receptor deficient mice.
Cardiomyopathies
BAY60-2770 attenuates doxorubicin-induced cardiotoxicity by decreased oxidative stress and enhanced autophagy.
Distinct Myocardial Mechanisms Underlie Cardiac Dysfunction in Endotoxemic Male and Female Mice.
Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical Trial.
Endogenous cardiac natriuretic peptides protect the heart in a mouse model of dilated cardiomyopathy and sudden death.
Metabolic and signaling alterations in dystrophin-deficient hearts precede overt cardiomyopathy.
Cardiomyopathy, Dilated
Endogenous cardiac natriuretic peptides protect the heart in a mouse model of dilated cardiomyopathy and sudden death.
Cardiotoxicity
Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection.
Decreased Soluble Guanylate Cyclase Contributes to Cardiac Dysfunction Induced by Chronic Doxorubicin Treatment in Mice.
Inhibition of cardiac guanylate cyclase by doxorubicin and some of its analogs: possible relationship to cardiotoxicity.
Lack of correlation between effects of anthracyclines on in vitro cardiac guanyl cyclase and in vivo cardiotoxicity.
Selective inhibition of rat and human cardiac guanylate cyclase by doxorubicin (adriamycin): possible link to anthracycline cardiotoxicity.
Selective inhibition of rat and human cardiac guanylate cyclase in vitro by doxorubicin (adriamycin): possible link to anthracycline cardiotoxicity.
The sGC-cGMP Signaling Pathway as a Potential Therapeutic Target in Doxorubicin-Induced Heart Failure: A Narrative Review.
Cardiovascular Diseases
C-type natriuretic peptide: A new cardiac mediator.
Cardiovascular and pharmacological implications of haem-deficient NO-unresponsive soluble guanylate cyclase knock-in mice.
Comparison of soluble guanylate cyclase stimulators and activators in models of cardiovascular disease associated with oxidative stress.
Design, Synthesis, and Actions of an Innovative Bispecific Designer Peptide.
Discovery of IWP-051, a Novel Orally Bioavailable sGC Stimulator with Once-Daily Dosing Potential in Humans.
Discovery of stimulator binding to a conserved pocket in the heme domain of soluble guanylyl cyclase.
Enhancing cardiovascular dynamics by inhibition of thrombospondin-1/CD47 signaling.
Genetic variation at the coronary artery disease risk locus GUCY1A3 modifies cardiovascular disease prevention effects of aspirin.
In vitro inactivation of mammalian methionine synthase by nitric oxide.
Molecular Model of a Soluble Guanylyl Cyclase Fragment Determined by Small-Angle X-ray Scattering and Chemical Cross-Linking.
Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models.
Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease.
NO-sensitive guanylyl cyclase and NO-induced feedback inhibition in cGMP signaling.
Omentin changes following bariatric surgery and predictive links with biomarkers for risk of cardiovascular disease.
Significant pharmacokinetic and pharmacodynamic interaction of warfarin with the NO-independent sGC activator HMR1766.
Soluble guanylate cyclase as a novel treatment target for osteoporosis.
Soluble guanylyl cyclase activator YC-1 inhibits human neutrophil functions through a cGMP-independent but cAMP-dependent pathway.
Soluble guanylyl cyclase: physiological role as an NO receptor and the potential molecular target for therapeutic application.
Solution structures of the Shewanella woodyi H-NOX protein in the presence and absence of soluble guanylyl cyclase stimulator IWP-051.
Stimulators of the soluble guanylyl cyclase: promising functional insights from rare coding atherosclerosis-related GUCY1A3 variants.
Structure of cinaciguat (BAY 58-2667) bound to Nostoc H-NOX domain reveals insights into heme-mimetic activation of the soluble guanylyl cyclase.
Targeting heme-oxidized soluble guanylate cyclase in experimental heart failure.
Targeting transcriptional control of soluble guanylyl cyclase via NOTCH for prevention of cardiovascular disease.
The Endothelium-Dependent Nitric Oxide-cGMP Pathway.
The impact of nitric oxide in cardiovascular medicine: untapped potential utility.
The molecular mechanism of heme loss from oxidized soluble guanylate cyclase induced by conformational change.
The sGC stimulator riociguat inhibits platelet function in washed platelets but not in whole blood.
The Soluble Guanylate Cyclase Stimulator Riociguat Ameliorates Pulmonary Hypertension Induced by Hypoxia and SU5416 in Rats.
The soluble guanylate cyclase stimulator riociguat and the soluble guanylate cyclase activator cinaciguat exert no direct effects on contractility and relaxation of cardiac myocytes from normal rats.
The Soluble Guanylyl Cyclase Activator BAY 60-2770 Ameliorates Overactive Bladder in Obese Mice.
Catalepsy
Intracerebroventricular administration of nitric oxide-sensitive guanylyl cyclase inhibitors induces catalepsy in mice.
Cerebral Infarction
[Effects of electroacupuncture "Shuigou" on expression of soluble guanylate cyclase(sGC) and protein kinase G (PKG)in vascular smooth muscle of cerebral artery in rats with cerebral infarction].
Cerebrovascular Trauma
VEGF increases permeability of the blood-brain barrier via a nitric oxide synthase/cGMP-dependent pathway.
Cholangiocarcinoma
Guanylin regulates chloride secretion in the human gallbladder via the bile fluid.
Secretin receptors in the human liver: expression in biliary tract and cholangiocarcinoma, but not in hepatocytes or hepatocellular carcinoma.
Cholera
A simple, sensitive, and specific assay for the heat-stable enterotoxin of Escherichia coli.
Effects of G protein and cGMP on phytochrome-mediated amaranthin synthesis inAmaranthus caudatus seedlings.
From Escherichia coli heat-stable enterotoxin to mammalian endogenous guanylin hormones.
Gaseous ligand selectivity of the H-NOX sensor protein from Shewanella oneidensis and comparison to those of other bacterial H-NOXs and soluble guanylyl cyclase.
Inhibition of guanylate cyclase and cyclic GMP phosphodiesterase by cholera toxin.
Mode of action of heat-stable Escherichia coli enterotoxin. Tissue and subcellular specificities and role of cyclic GMP.
Choriocarcinoma
Expression and function of autocrine motility factor receptor in human choriocarcinoma.
Cocarcinogenesis
Biochemical evidence of cocarcinogenesis: tumor promoting agent enhances methylnitrosourea activation of rat guanylate cyclase activity.
Colitis
Decrease of guanylyl cyclase ?1 subunit and nitric oxide (NO)-induced relaxation in mouse rectum with colitis and its reproduction on long-term NO treatment.
Engineering of an Anti-Inflammatory Peptide Based on the Disulfide-Rich Linaclotide Scaffold.
Guanylate cyclase C deficiency causes severe inflammation in a murine model of spontaneous colitis.
Influence of soluble guanylate cyclase inhibition on inflammation and motility disturbances in DSS-induced colitis.
Colitis, Ulcerative
Pharmacology and clinical potential of guanylyl cyclase C agonists in the treatment of ulcerative colitis.
Colonic Neoplasms
Analytical performance of a qRT-PCR assay to detect guanylyl cyclase C in FFPE lymph nodes of patients with colon cancer.
Bacterial enterotoxins are associated with resistance to colon cancer.
Comparison of histopathology and RT-qPCR amplification of guanylyl cyclase C for detection of colon cancer metastases in lymph nodes.
Cross talk between receptor guanylyl cyclase C and c-src tyrosine kinase regulates colon cancer cell cytostasis.
Evaluation of Guanylyl Cyclase C Lymph Node Status for Colon Cancer Staging and Prognosis.
Exisulind and guanylyl cyclase C induce distinct antineoplastic signaling mechanisms in human colon cancer cells.
Guanylyl cyclase C prevents colon cancer metastasis by regulating tumor epithelial cell matrix metalloproteinase-9.
Guanylyl cyclase C signaling axis and colon cancer prevention.
In vitro and in vivo comparison of human Escherichia coli heat-stable peptide analogues incorporating the 111In-DOTA group and distinct linker moieties.
In vitro and in vivo evaluation of 177Lu- and 90Y-labeled E. coli heat-stable enterotoxin for specific targeting of uroguanylin receptors on human colon cancers.
In vivo evaluation of an 111In-labeled ST-peptide analog for specific-targeting of human colon cancers.
In vivo imaging of human colon cancer xenografts in immunodeficient mice using a guanylyl cyclase C--specific ligand.
Interruption of homologous desensitization in cyclic guanosine 3',5'-monophosphate signaling restores colon cancer cytostasis by bacterial enterotoxins.
Lineage-specific T-cell responses to cancer mucosa antigen oppose systemic metastases without mucosal inflammatory disease.
Molecular testing for lymph node metastases as a determinant of colon cancer recurrence: results from a retrospective multicenter study.
Obesity-Induced Colorectal Cancer Is Driven by Caloric Silencing of the Guanylin-GUCY2C Paracrine Signaling Axis.
Prognostic Value of Molecular Detection of Lymph Node Metastases After Curative Resection of Stage II Colon Cancer: A Systematic Pooled Data Analysis.
Proliferative signaling by store-operated calcium channels opposes colon cancer cell cytostasis induced by bacterial enterotoxins.
Synthesis and in vitro evaluation of an 111In-labeled ST-peptide enterotoxin (ST) analogue for specific targeting of guanylin receptors on human colonic cancers.
Thermodynamic analyses reveal role of water release in epitope recognition by a monoclonal antibody against the human guanylyl cyclase C receptor.
Use of guanylyl cyclase C for detecting micrometastases in lymph nodes of patients with colon cancer.
Colorectal Neoplasms
A monomethyl auristatin E-conjugated antibody to guanylyl cyclase C is cytotoxic to target-expressing cells in vitro and in vivo.
A Pilot Study of CK19, CK20 and GCC mRNA in the Peripheral Blood as a Colorectal Cancer Biomarker Panel.
A splice variant of the transcript for guanylyl cyclase C is expressed in human colon and colorectal cancer cells.
A validated quantitative assay to detect occult micrometastases by reverse transcriptase-polymerase chain reaction of guanylyl cyclase C in patients with colorectal cancer.
An update on guanylyl cyclase C in the diagnosis, chemoprevention, and treatment of colorectal cancer.
Association of GUCY2C expression in lymph nodes with time to recurrence and disease-free survival in pN0 colorectal cancer.
Comparative evaluation of three 64Cu-labeled E. coli heat-stable enterotoxin analogues for PET imaging of colorectal cancer.
Corruption of homeostatic mechanisms in the guanylyl cyclase C signaling pathway underlying colorectal tumorigenesis.
Cytokeratin 20 and guanylyl cyclase C mRNA is largely present in lymph node and liver specimens of colorectal cancer patients.
Cytokine adjuvanation of therapeutic anti-tumor immunity targeted to cancer mucosa antigens.
Detection of cytokeratins 19/20 and guanylyl cyclase C in peripheral blood of colorectal cancer patients.
Discordant quantitative detection of putative biomarkers in nodal micrometastases of colorectal cancer: biological and clinical implications.
Does stage II colorectal cancer need to be redefined?
Ectopic expression of guanylyl cyclase C in adenocarcinomas of the esophagus and stomach.
Ectopic expression of guanylyl cyclase C in CD34+ progenitor cells in peripheral blood.
Enterotoxin preconditioning restores calcium-sensing receptor-mediated cytostasis in colon cancer cells.
Escherichia coli heat-stable enterotoxin receptors. A novel marker for colorectal tumors.
Expression of the intestinal biomarkers Guanylyl cyclase C and CDX2 in poorly differentiated colorectal carcinomas.
Guanylate cyclase C as a target for prevention, detection, and therapy in colorectal cancer.
Guanylyl cyclase C as a biomarker for immunotherapies for the treatment of gastrointestinal malignancies.
Guanylyl cyclase C as a biomarker for targeted imaging and therapy of metastatic colorectal cancer.
Guanylyl cyclase C as a biomarker in colorectal cancer.
Guanylyl cyclase C as a reliable immunohistochemical marker and its ligand Escherichia coli heat-stable enterotoxin as a potential protein-delivering vehicle for colorectal cancer cells.
Guanylyl Cyclase C Hormone Axis at the Intersection of Obesity and Colorectal Cancer.
Guanylyl cyclase C in colorectal cancer: susceptibility gene and potential therapeutic target.
Guanylyl cyclase C is a marker of intestinal metaplasia, dysplasia, and adenocarcinoma of the gastrointestinal tract.
Guanylyl cyclase C is a selective marker for metastatic colorectal tumors in human extraintestinal tissues.
Guanylyl cyclase C messenger RNA is a biomarker for recurrent stage II colorectal cancer.
Guanylyl cyclase C prevents colon cancer metastasis by regulating tumor epithelial cell matrix metalloproteinase-9.
Guanylyl cyclase C-induced immunotherapeutic responses opposing tumor metastases without autoimmunity.
Guanylyl cyclase C: a molecular marker for staging and postoperative surveillance of patients with colorectal cancer.
GUCY2C lysosomotropic endocytosis delivers immunotoxin therapy to metastatic colorectal cancer.
GUCY2C-targeted cancer immunotherapy: past, present and future.
Heterogeneity of guanylyl cyclase C expressed by human colorectal cancer cell lines in vitro.
Impact of circulating free tumor cells in the peripheral blood of colorectal cancer patients during laparoscopic surgery.
In vitro and in vivo evaluation of 111In-labeled E. coli heat-stable enterotoxin analogs for specific targeting of human breast cancers.
Intestinal GUCY2C Prevents TGF-? Secretion Coordinating Desmoplasia and Hyperproliferation in Colorectal Cancer.
Intrinsic variability in the detection of micrometastases in lymph nodes for re-staging of colorectal cancer. effect of individual markers and tissue samples.
Lymph node CEA and MUC2 mRNA as useful predictors of outcome in colorectal cancer.
Molecular staging of node negative patients with colorectal cancer.
Mucosally restricted antigens as novel immunological targets for antitumor therapy.
Opportunities for near-infrared thermal ablation of colorectal metastases by guanylyl cyclase C-targeted gold nanoshells.
Optimizing the radiosynthesis of [68Ga]DOTA-MLN6907 peptide containing three disulfide cyclization bonds - a GCC specific chelate for clinical radiopharmaceuticals.
Peripheral blood guanylyl cyclase c (GCC) expressions are associated with prognostic parameters and response to therapy in colorectal cancer patients.
Phosphorylation of vasodilator-stimulated phosphoprotein Ser239 suppresses filopodia and invadopodia in colon cancer.
Preclinical Evaluation of 89Zr-Df-IAB22M2C PET as an Imaging Biomarker for the Development of the GUCY2C-CD3 Bispecific PF-07062119 as a T Cell Engaging Therapy.
Preclinical Evaluation of a Replication-Deficient Recombinant Adenovirus Serotype 5 Vaccine Expressing Guanylate Cyclase C and the PADRE T-helper Epitope.
Previstage GCC Colorectal Cancer Staging Test: A New Molecular Test to Identify Lymph Node Metastases and Provide More Accurate Information about the Stage of Patients with Colorectal Cancer.
Previstage GCC test for staging patients with colorectal cancer.
Previstagetrade mark GCC test for staging patients with colorectal cancer.
Proliferative signaling by store-operated calcium channels opposes colon cancer cell cytostasis induced by bacterial enterotoxins.
Quantification of cytokeratin 20, carcinoembryonic antigen and guanylyl cyclase C mRNA levels in lymph nodes may not predict treatment failure in colorectal cancer patients.
Radiometallated peptides targeting guanylate cyclase C and the urokinase-type plasminogen activator receptor.
Relative quantification based on logistic models for individual polymerase chain reactions.
Selective antigen-specific CD4(+) T-cell, but not CD8(+) T- or B-cell, tolerance corrupts cancer immunotherapy.
Sphingomyelin nanosystems loaded with uroguanylin and etoposide for treating metastatic colorectal cancer.
STa peptide analogs for probing guanylyl cyclase C.
Statistical algorithm for assuring similar efficiency in standards and samples for absolute quantification by real-time reverse transcription polymerase chain reaction.
The Heat-Stable Enterotoxin Receptor, Guanylyl Cyclase C, as a Pharmacological Target in Colorectal Cancer Immunotherapy: A Bench-to-Bedside Current Report.
The shifting paradigm of colorectal cancer treatment: a look into emerging cancer stem cell-directed therapeutics to lead the charge toward complete remission.
Translating colorectal cancer prevention through the guanylyl cyclase C signaling axis.
Use of guanylyl cyclase C for detecting micrometastases in lymph nodes of patients with colon cancer.
[Detection of guanylate cyclase C mRNA and cytokeratin 20 mRNA in peripheral blood and analysis of prognosis in early to moderate colorectal cancer patients].
Cone Dystrophy
A mutation in guanylate cyclase activator 1A (GUCA1A) in an autosomal dominant cone dystrophy pedigree mapping to a new locus on chromosome 6p21.1.
Ca(2+)-binding proteins in the retina: from discovery to etiology of human disease(1).
Calcium binding, structural stability and guanylate cyclase activation in GCAP1 variants associated with human cone dystrophy.
Calcium binding, structural stability and guanylate cyclase activation in GCAP1 variants associated with human cone dystrophy.
Cone dystrophy or macular dystrophy associated with novel autosomal dominant GUCA1A mutations.
Dominant cone and cone-rod dystrophies: functional analysis of mutations in retGC1 and GCAP1.
Dominant Cone-Rod Dystrophy: A Mouse Model Generated by Gene Targeting of the GCAP1/Guca1a Gene.
Functional characterization of a novel GUCA1A missense mutation (D144G) in autosomal dominant cone dystrophy: A novel pathogenic GUCA1A variant in COD.
Mutations in the GUCA1A gene involved in hereditary cone dystrophies impair calcium-mediated regulation of guanylate cyclase.
Rapid cohort generation and analysis of disease spectrum of large animal model of cone dystrophy.
Cone-Rod Dystrophies
A Gly86Arg mutation in the calcium-sensor protein GCAP1 alters regulation of retinal guanylyl cyclase and causes dominant cone-rod degeneration.
A novel mutation in the GUCY2D gene responsible for an early onset severe RP different from the usual GUCY2D-LCA phenotype.
Autosomal dominant cone and cone-rod dystrophy with mutations in the guanylate cyclase activator 1A gene-encoding guanylate cyclase activating protein-1.
Autosomal dominant cone-rod dystrophy due to a missense mutation (R838C) in the guanylate cyclase 2D gene (GUCY2D) with preserved rod function in one branch of the family.
Autosomal dominant cone-rod dystrophy with mutations in the guanylate cyclase 2D gene encoding retinal guanylate cyclase-1.
Autosomal dominant cone-rod retinal dystrophy (CORD6) from heterozygous mutation of GUCY2D, which encodes retinal guanylate cyclase.
Biochemical analysis of a dimerization domain mutation in RetGC-1 associated with dominant cone-rod dystrophy.
Clustering and frequency of mutations in the retinal guanylate cyclase (GUCY2D) gene in patients with dominant cone-rod dystrophies.
Cone dystrophy or macular dystrophy associated with novel autosomal dominant GUCA1A mutations.
Dominant cone and cone-rod dystrophies: functional analysis of mutations in retGC1 and GCAP1.
Factors that affect regulation of cGMP synthesis in vertebrate photoreceptors and their genetic link to human retinal degeneration.
Functional characterization of missense mutations at codon 838 in retinal guanylate cyclase correlates with disease severity in patients with autosomal dominant cone-rod dystrophy.
Genetic analysis of the guanylate cyclase activator 1B (GUCA1B) gene in patients with autosomal dominant retinal dystrophies.
Guanylate cyclase activating proteins, guanylate cyclase and disease.
GUCY2D Cone-Rod Dystrophy-6 Is a "Phototransduction Disease" Triggered by Abnormal Calcium Feedback on Retinal Membrane Guanylyl Cyclase 1.
GUCY2D mutations in retinal guanylyl cyclase 1 provide biochemical reasons for dominant cone-rod dystrophy but not for stationary night blindness.
Impairment of the rod outer segment membrane guanylate cyclase dimerization in a cone-rod dystrophy results in defective calcium signaling.
Leber congenital amaurosis.
Mutations in the retinal guanylate cyclase (RETGC-1) gene in dominant cone-rod dystrophy.
Mutations in the rod outer segment membrane guanylate cyclase in a cone-rod dystrophy cause defects in calcium signaling.
Novel complex GUCY2D mutation in Japanese family with cone-rod dystrophy.
Novel GUCA1A mutation identified in a Chinese family with cone-rod dystrophy.
Phenotype of autosomal dominant cone-rod dystrophy due to the R838C mutation of the GUCY2D gene encoding retinal guanylate cyclase-1.
Photoreceptor Guanylate Cyclase (GUCY2D) Mutations Cause Retinal Dystrophies by Severe Malfunction of Ca2+-Dependent Cyclic GMP Synthesis.
Regulation of cGMP synthesis in photoreceptors: role in signal transduction and congenital diseases of the retina.
Retinal degeneration-3 protein attenuates photoreceptor degeneration in transgenic mice expressing dominant mutation of human retinal guanylyl cyclase.
Retinal diseases linked with photoreceptor guanylate cyclase.
Spectrum of retGC1 mutations in Leber's congenital amaurosis.
The dimerization domain in outer segment guanylate cyclase is a Ca²?-sensitive control switch module.
Variants at codon 838 in the GUCY2D gene result in different phenotypes of cone rod dystrophy.
Congenital Abnormalities
An activating mutation in the kinase homology domain of the natriuretic peptide receptor-2 causes extremely tall stature without skeletal deformities.
Contracture
The role of the NO/NMDA pathways in the development of morphine withdrawal induced by naloxone in vitro.
Coronary Artery Disease
Computational exploration of the binding mode of heme-dependent stimulators into the active catalytic domain of soluble guanylate cyclase.
Identification of a soluble guanylate cyclase in RBCs: preserved activity in patients with coronary artery disease.
Coronary Disease
Purification and characterization of NO-sensitive guanylyl cyclase.
[Functional activity of platelet guanylate cyclase and cardiac hemodynamics in patients with chronic heart failure and relevant changes after treatment with isosorbide-5-mononitrate]
Creutzfeldt-Jakob Syndrome
Reduced expression of NO-sensitive guanylyl cyclase in reactive astrocytes of Alzheimer disease, Creutzfeldt-Jakob disease, and multiple sclerosis brains.
Crohn Disease
Guanylate Cyclase C Activation Shapes the Intestinal Microbiota in Patients with Familial Diarrhea and Increased Susceptibility for Crohn's Disease.
Cryptorchidism
Tissue guanosine-3',5'-cyclic monophosphate levels and soluble guanylate cyclase activity: a positive correlation during unilateral cryptorchidism in the rat testis.
Cystic Fibrosis
Benefit-Risk Assessment of Plecanatide in the Treatment of Chronic Idiopathic Constipation.
C-type natriuretic peptide increases chloride permeability in normal and cystic fibrosis airway cells.
Cellular effects of guanylin and uroguanylin.
Cl- transport in an immortalized human epithelial cell line (NCM460) derived from the normal transverse colon.
Clara cell impact in air-side activation of CFTR in small pulmonary airways.
DETANO and nitrated lipids increase chloride secretion across lung airway cells.
Duodenal bicarbonate secretion in rats: stimulation by intra-arterial and luminal guanylin and uroguanylin.
Emerging pharmacologic therapies for irritable bowel syndrome.
Guanylin and related peptides.
Guanylin mRNA expression in human intestine and colorectal adenocarcinoma.
Interruption of transmembrane signaling as a novel antisecretory strategy to treat enterotoxigenic diarrhea.
Linaclotide Improves Gastrointestinal Transit in Cystic Fibrosis Mice by Inhibiting Sodium/Hydrogen Exchanger 3.
Linaclotide: a new option for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation in adults.
Regulation of amiloride-sensitive sodium absorption in murine airway epithelium by C-type natriuretic peptide.
Regulation of intestinal gene expression by dietary zinc: induction of uroguanylin mRNA by zinc deficiency.
Riociguat for the treatment of Phe508del homozygous adults with cystic fibrosis.
Uroguanylin and guanylate cyclase C in the human pancreas: expression and mutuality of ligand/receptor localization as indicators of intercellular paracrine signaling pathways.
Cystitis
Activation of soluble guanylyl cyclase by BAY 58-2667 improves bladder function in cyclophosphamide-induced cystitis in mice.
Cystitis, Interstitial
Urinary nitric oxide synthase activity and cyclic GMP levels are decreased with interstitial cystitis and increased with urinary tract infections.
Cysts
Characterisation of guanylyl cyclase genes in the soybean cyst nematode, Heterodera glycines.
Cyclic GMP controls Rhodospirillum centenum cyst development.
DNA-binding properties of a cGMP-binding CRP homologue that controls development of metabolically dormant cysts of Rhodospirillum centenum.
Dehydration
Tonicity-dependent induction of Sgk1 expression has a potential role in dehydration-induced natriuresis in rodents.
Dementia
VIP-sensitive adenylate cyclase, guanylate cyclase, muscarinic receptors, choline acetyltransferase and acetylcholinesterase, in brain tissue afflicted by Alzheimer's disease/senile dementia of the Alzheimer type.
Diabetes Complications
Supplementation with Phycocyanobilin, Citrulline, Taurine, and Supranutritional Doses of Folic Acid and Biotin-Potential for Preventing or Slowing the Progression of Diabetic Complications.
Diabetes Mellitus
Bioactive compounds in plant materials for the prevention of diabetesand obesity.
Decreased rat hepatic guanylate cyclase activity in streptozotocin-induced diabetes mellitus.
Guanylate cyclase activity in rat liver and other tissues with starvation and streptozotocin-induced diabetes mellitus.
Guanylate cyclase in human platelets with different aggregability.
Nitric oxide-dependent soluble guanylate cyclase activity is decreased in platelets from male NIDDM patients.
The soluble guanylate cyclase activator cinaciguat prevents cardiac dysfunction in a rat model of type-1 diabetes mellitus.
[ADP-induced aggregation of human platelets in diabetes mellitus]
[Human thrombocyte guanylate cyclase in diabetes mellitus]
[Relation between human platelet aggregation and activation of soluble platelet guanylate cyclase]
Diabetes Mellitus, Experimental
Soluble guanylyl cyclase activation with HMR1766 attenuates platelet activation in diabetic rats.
Diabetes Mellitus, Type 2
An exploratory, randomised, placebo-controlled, 14 day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertension.
Bioactive compounds in plant materials for the prevention of diabetesand obesity.
Nitric oxide-dependent soluble guanylate cyclase activity is decreased in platelets from male NIDDM patients.
Reduced vascular responses to soluble guanylyl cyclase but increased sensitivity to sildenafil in female rats with type 2 diabetes.
Diabetic Cardiomyopathies
Heart specific up-regulation of genes for B-type and C-type natriuretic peptide receptors in diabetic mice.
The soluble guanylate cyclase activator cinaciguat prevents cardiac dysfunction in a rat model of type-1 diabetes mellitus.
Diabetic Nephropathies
A Soluble Guanylate Cyclase Activator Inhibits the Progression of Diabetic Nephropathy in the ZSF1 Rat.
Effects of Stimulation of Soluble Guanylate Cyclase on Diabetic Nephropathy in Diabetic eNOS Knockout Mice on Top of Angiotensin II Receptor Blockade.
Effects of the Soluble Guanylate Cyclase Stimulator Praliciguat in Diabetic Kidney Disease: A Randomized Placebo-Controlled Clinical Trial.
[Endothelial relaxation factor in the development of diabetic nephropathy]
Diabetic Retinopathy
Aberrant utilization of nitric oxide and regulation of soluble guanylate cyclase in rat diabetic retinopathy.
Donohue Syndrome
Decreased cyclic guanosine 3',5' monophosphate and guanylate cyclase activity in leprechaunism: evidence for a postreceptor defect.
Ductus Arteriosus, Patent
Role of cyclic nucleotides in relaxation of fetal lamb ductus arteriosus.
Dwarfism
C-type natriuretic peptide in growth: a new paradigm.
Catalytically Active Guanylyl Cyclase B Requires Endoplasmic Reticulum-mediated Glycosylation, and Mutations That Inhibit This Process Cause Dwarfism.
Defective cellular trafficking of missense NPR-B mutants is the major mechanism underlying acromesomelic dysplasia-type Maroteaux.
Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions.
Prevention of guanylyl cyclase-B dephosphorylation rescues achondroplastic dwarfism.
Reduced ability of C-type natriuretic peptide (CNP) to activate natriuretic peptide receptor B (NPR-B) causes dwarfism in lbab -/- mice.
Dysentery, Bacillary
[Prostaglandins and cyclic nucleotides in the gastrointestinal form of yersiniosis]
Dyskinesias
Repurposing an established drug: an emerging role for methylene blue in L-DOPA-induced dyskinesia.
Dystonia
Neurotoxicity in conscious rats following intraventricular SNAP, a nitric oxide donor.
Endotoxemia
Desensitization of soluble guanylate cyclase in renal cortex during endotoxemia in mice.
Guanylyl Cyclase A in Both Renal Proximal Tubular and Vascular Endothelial Cells Protects the Kidney against Acute Injury in Rodent Experimental Endotoxemia Models.
Nitric oxide modifies the sarcoplasmic reticular calcium release channel in endotoxemia by both guanosine-3',5' (cyclic) phosphate-dependent and independent pathways.
Nitric oxide-dependent reduction in soluble guanylate cyclase functionality accounts for early lipopolysaccharide-induced changes in vascular reactivity.
Nitric oxide-independent activation of soluble guanylyl cyclase contributes to endotoxin shock in rats.
Selective inhibition of guanylate cyclase prevents impairment of hypoxic pulmonary vasoconstriction in endotoxemic mice.
Enterocolitis, Pseudomembranous
Purified Clostridium difficile cytotoxin stimulates guanylate cyclase activity and inhibits adenylate cyclase activity.
Erectile Dysfunction
A Rho-kinase inhibitor, soluble guanylate cyclase activator and nitric oxide-releasing PDE5 inhibitor: novel approaches to erectile dysfunction.
Activators of soluble guanylate cyclase for the treatment of male erectile dysfunction.
Adenylate and guanylate cyclase activity in the penis and aorta of the diabetic rat: an in vitro study.
Analysis of Erectile Responses to BAY 41-8543 and Muscarinic Receptor Stimulation in the Rat.
BAY 41-2272: a stimulator of soluble guanylyl cyclase induces nitric oxide-dependent penile erection in vivo.
cGMP: transition from bench to bedside: a report of the 6th International Conference on cGMP Generators, Effectors and Therapeutic Implications.
Computational exploration of the binding mode of heme-dependent stimulators into the active catalytic domain of soluble guanylate cyclase.
Constitutive LH receptor activity impairs NO-mediated penile smooth muscle relaxation.
Erectile Dysfunction in Heme-Deficient Nitric Oxide-Unresponsive Soluble Guanylate Cyclase Knock-In Mice.
Exploring the Potential of No-Independent Stimulators and Activators of Soluble Guanylate Cyclase for the Medical Treatment of Erectile Dysfunction.
Extending the translational potential of targeting NO/cGMP-regulated pathways in the CVS.
Hypercontractility and impaired sildenafil relaxations in the BKCa channel deletion model of erectile dysfunction.
Membrane bound guanylyl cyclase as a potential molecular target for the treatment of erectile dysfunction.
Modulation of soluble guanylate cyclase for the treatment of erectile dysfunction.
Oral phosphodiesterase-5 inhibitors and sperm functions.
Role of the soluble guanylyl cyclase alpha1-subunit in mice corpus cavernosum smooth muscle relaxation.
Soluble guanylate cyclase beta1-subunit expression is increased in mononuclear cells from patients with erectile dysfunction.
Soluble guanylyl cyclase: physiological role as an NO receptor and the potential molecular target for therapeutic application.
The Endothelium-Dependent Nitric Oxide-cGMP Pathway.
Yohimbine relaxes the human corpus cavernosum through a non-adrenergic mechanism involving the activation of K(+)ATP-dependent channels.
Esophageal Achalasia
Loss of ?1?1 Soluble Guanylate Cyclase, the Major Nitric Oxide Receptor, Leads to Moyamoya and Achalasia.
Essential Hypertension
Association of CT dinucleotide repeat polymorphism in the 5'-flanking region of the guanylyl cyclase (GC)-A gene with essential hypertension in the Japanese.
Haplotype-based case-control study of the association between the guanylate cyclase activator 2B (GUCA2B, Uroguanylin) gene and essential hypertension.
Soluble guanylate cyclase contribute genetic susceptibility to essential hypertension in the Han Chinese population.
Eye Diseases
Autosomal dominant cone-rod dystrophy due to a missense mutation (R838C) in the guanylate cyclase 2D gene (GUCY2D) with preserved rod function in one branch of the family.
Familial Primary Pulmonary Hypertension
Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension.
Fatty Liver
The soluble guanylate cyclase stimulator IW-1973 prevents inflammation and fibrosis in experimental non-alcoholic steatohepatitis.
Fetal Growth Retardation
Soluble guanylate cyclase stimulation in late gestation does not mitigate asymmetric intrauterine growth restriction or cardiovascular risk induced by placental ischemia in the rat.
Stimulation of soluble guanylate cyclase diminishes intrauterine growth restriction in a rat model of placental ischemia.
The soluble guanylate cyclase inhibitor methylene blue evokes preterm delivery and fetal growth restriction in a mouse model.
Ganglioneuroblastoma
Substance-P receptors in human primary neoplasms: tumoral and vascular localization.
Gastrointestinal Diseases
Emerging treatments in Neurogastroenterology: Perspectives of guanylyl cyclase C agonists use in functional gastrointestinal disorders and inflammatory bowel diseases.
Linaclotide, a synthetic guanylate cyclase C agonist, for the treatment of functional gastrointestinal disorders associated with constipation.
Gastrointestinal Neoplasms
Consistent expression of guanylyl cyclase-C in primary and metastatic gastrointestinal cancers.
Guanylyl cyclase 2C (GUCY2C) in gastrointestinal cancers: recent innovations and therapeutic potential.
Gastroparesis
Heme deficiency of soluble guanylate cyclase induces gastroparesis.
Natriuretic Peptide-Dependent cGMP Signal Pathway Potentiated the Relaxation of Gastric Smooth Muscle in Streptozotocin-Induced Diabetic Rats.
Glaucoma
A Randomized, Controlled Phase I/II Study to Evaluate the Safety and Efficacy of MGV354 for Ocular Hypertension or Glaucoma.
Soluble Guanylate Cyclase ?1-Deficient Mice: A Novel Murine Model for Primary Open Angle Glaucoma.
Soluble Guanylate Cyclase a1-Deficient Mice: a novel murine model for Primary Open Angle Glaucoma.
The Discovery of ( S)-1-(6-(3-((4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1 H-inden-4-yl)pyridin-2-yl)-5-methyl-1 H-pyrazole-4-carboxylic Acid, a Soluble Guanylate Cyclase Activator Specifically Designed for Topical Ocular Delivery as a Therapy for Glaucoma.
Glaucoma, Open-Angle
Soluble Guanylate Cyclase ?1-Deficient Mice: A Novel Murine Model for Primary Open Angle Glaucoma.
Soluble Guanylate Cyclase a1-Deficient Mice: a novel murine model for Primary Open Angle Glaucoma.
Glioblastoma
Regulation of the cyclic guanosine 3'-5' monophosphate system in human brain tumors.
Glioma
Cellular antitumor immune response to a branched lysine multiple antigenic peptide containing epitopes of a common tumor-specific antigen in a rat glioma model.
Comparison of a cloned ANF-sensitive guanylate cyclase (GC-A) with particulate guanylate cyclase from adrenal cortex.
Detection of membrane-bound guanylate cyclase activity in rat C6 glioma cells at different growth states following activation by natriuretic peptides.
Effects of three distinct natriuretic peptides on receptor binding and guanylate cyclase activities in rat glioma cells.
Inhibition of angiogenesis in human glioma cell lines by antisense RNA from the soluble guanylate cyclase genes, GUCY1A3 and GUCY1B3.
Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced glioma cells.
Restoring soluble guanylyl cyclase expression and function blocks the aggressive course of glioma.
Selective activation of particulate guanylate cyclase by a specific class of porphyrins.
[Effect of GM3 ganglioside on the adenyl and guanyl cyclase activity of cultured cells]
Glomerulonephritis
Expression and activity of soluble guanylate cyclase in injury and repair of anti-thy1 glomerulonephritis.
Stimulation of soluble guanylate cyclase slows progression in anti-thy1-induced chronic glomerulosclerosis.
Stimulation of soluble guanylyl cyclase inhibits mesangial cell proliferation and matrix accumulation in experimental glomerulonephritis.
Glucose Intolerance
? Cell-specific deletion of guanylyl cyclase A, the receptor for atrial natriuretic peptide, accelerates obesity-induced glucose intolerance in mice.
Granuloma
Guanylate cyclase in carrageenin granuloma tissue of rat.
guanylate cyclase deficiency
AAV-mediated gene therapy in the guanylate cyclase (RetGC1/RetGC2) double knockout mouse model of Leber congenital amaurosis.
Anaphylactic shock depends on PI3K and eNOS-derived NO.
Determining consequences of retinal membrane guanylyl cyclase (RetGC1) deficiency in human Leber congenital amaurosis en route to therapy: residual cone-photoreceptor vision correlates with biochemical properties of the mutants.
Gene Therapy Fully Restores Vision to the All-Cone Nrl(-/-) Gucy2e(-/-) Mouse Model of Leber Congenital Amaurosis-1.
Guanylate cyclase C deficiency causes severe inflammation in a murine model of spontaneous colitis.
Insights gained from gene therapy in animal models of retGC1 deficiency.
Head Injuries, Closed
Zinc protoporphyrin IX attenuates closed head injury-induced edema formation, blood-brain barrier disruption, and serotonin levels in the rat.
Hearing Loss
Guanylyl Cyclase A/cGMP Signaling Slows Hidden, Age- and Acoustic Trauma-Induced Hearing Loss.
Heart Arrest
Protective effects of nitric oxide synthase 3 and soluble guanylate cyclase on the outcome of cardiac arrest and cardiopulmonary resuscitation in mice.
Heart Diseases
Post receptor determinants of acute platelet response to clopidogrel in patients with symptomatic myocardial ischemia.
Soluble guanylate cyclase stimulator riociguat and phosphodiesterase 5 inhibitor sildenafil ameliorate pulmonary hypertension due to left heart disease in mice.
The soluble guanylate cyclase stimulator IW-1973 prevents inflammation and fibrosis in experimental non-alcoholic steatohepatitis.
Heart Failure
?3-Adrenoceptor redistribution impairs NO/cGMP/PDE2 signalling in failing cardiomyocytes.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator: The VICTORIA Trial.
A novel soluble guanylate cyclase activator with reduced risk of hypotension by short-acting vasodilation.
Acute Hemodynamic Effects of Riociguat in Patients with Pulmonary Hypertension Associated with Diastolic Heart Failure (DILATE-1): A Randomized, Double-Blind, Placebo-Controlled, Single-Dose Study.
Acute stimulation of the soluble guanylate cyclase does not impact on left ventricular capacitance in normal and hypertrophied porcine hearts in vivo.
Arg13 of B-type natriuretic Peptide reciprocally modulates binding to guanylyl cyclase but not clearance receptors.
Assessment of the Effects of Renal Impairment on the Pharmacokinetics of the Soluble Guanylate Cyclase Activator Cinaciguat After a Single Intravenous Dose.
C-type natriuretic peptide transcriptomic profiling increases in human leukocytes of patients with chronic heart failure as a function of clinical severity.
Captopril and ANP: changes in renal hemodynamics, glomerular-ANP receptors and guanylate cyclase activity in rats with heart failure.
Cardiac fibrosis in end-stage human heart failure and the cardiac natriuretic peptide guanylyl cyclase system: regulation and therapeutic implications.
Cardiorenal and humoral properties of a novel direct soluble guanylate cyclase stimulator BAY 41-2272 in experimental congestive heart failure.
cGMP: transition from bench to bedside: a report of the 6th International Conference on cGMP Generators, Effectors and Therapeutic Implications.
Cinaciguat (BAY 58-2667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure.
Cinaciguat, a soluble guanylate cyclase activator for the potential treatment of acute heart failure.
Cinaciguat, a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure.
Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes.
Combining New Classes of Drugs for HFrEF: from Trials to Clinical Practice.
Comparison of the hemodynamic responses to molsidomine and isosorbide dinitrate in congestive heart failure.
Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection.
Differential regulation of membrane guanylyl cyclases in congestive heart failure: natriuretic peptide receptor (NPR)-B, Not NPR-A, is the predominant natriuretic peptide receptor in the failing heart.
Discovery of new therapeutic redox targets for cardioprotection against ischemia/reperfusion injury and heart failure.
Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure.
Drug Treatment of Heart Failure with Reduced Ejection Fraction: Defining the Role of Vericiguat.
Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial.
Effects of an orally active NO-releasing agent, CAS 936, and its active metabolite, 3754, on cardiac and coronary dynamics in normal conscious dogs and after pacing-induced heart failure.
Enhanced Cardiomyocyte Function in Hypertensive Rats With Diastolic Dysfunction and Human Heart Failure Patients After Acute Treatment With Soluble Guanylyl Cyclase (sGC) Activator.
Enhancement of endothelium-dependent vasodilation by low-dose nitroglycerin in patients with congestive heart failure.
Expression of C-type natriuretic peptide and of its receptor NPR-B in normal and failing heart.
From bedside to bench--meeting report of the 7th International Conference on cGMP "cGMP: generators, effectors and therapeutic implications" in Trier, Germany, from June 19th to 21st 2015.
Gene expression of C-type natriuretic peptide and of its specific receptor NPR-B in human leukocytes of healthy and heart failure subjects.
Glucocorticoids Improve Renal Responsiveness to ANP by Upregulating NPR-A Expression in the Renal Inner Medullary Collecting Duct in Decompensated Heart Failure.
Guanylyl cyclase activator ataciguat improves vascular function and reduces platelet activation in heart failure.
Heart Failure With Reduced Ejection Fraction: A Review.
Identification of small molecule NPR-B antagonists by high throughput screening - potential use in heart failure.
Impact of oral soluble guanylate cyclase stimulators in heart failure: A systematic review and Meta-analysis of randomized controlled trials.
Metabolic Syndrome Mediates ROS-miR-193b-NFYA-Dependent Downregulation of Soluble Guanylate Cyclase and Contributes to Exercise-Induced Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction.
Metabolism and Pharmacokinetic Drug-Drug Interaction Profile of Vericiguat, A Soluble Guanylate Cyclase Stimulator: Results From Preclinical and Phase I Healthy Volunteer Studies.
Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions.
Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models.
Nitric oxide-sensitive guanylyl cyclase stimulation improves experimental heart failure with preserved ejection fraction.
Novel analog of atrial natriuretic peptide selective for receptor-A produces increased diuresis and natriuresis in rats.
NPR-B, the C-type natriuretic peptide specific receptor, is the predominant biological receptor in mouse and pig myocardial tissue.
Outcomes With sGC Therapy in Patients With HFpEF: A Meta-Analysis of Prior Trials.
Pacing-induced cardiac failure of hypertrophic hearts: effects of cyclic GMP reduction.
Patient-reported outcomes in the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED ejection fraction (SOCRATES-PRESERVED) study.
Pharmacodynamic and Pharmacokinetic Interaction Profile of Vericiguat: Results from Three Randomized Phase I Studies in Healthy Volunteers.
Pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase activator cinaciguat (BAY 58-2667) in healthy male volunteers.
Population pharmacokinetics and pharmacodynamics of cinaciguat, a soluble guanylate cyclase activator, in patients with acute decompensated heart failure.
Population Pharmacokinetics and Pharmacodynamics of Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction.
Possibility of downregulation of atrial natriuretic peptide receptor coupled to guanylate cyclase in peripheral vascular beds of patients with chronic severe heart failure.
Prevention of endothelial dysfunction in heart failure by vitamin E: attenuation of vascular superoxide anion formation and increase in soluble guanylyl cyclase expression.
Rationale and design for a multicenter, randomized, double-blind, placebo-controlled, phase 2 study evaluating the safety and efficacy of the soluble guanylate cyclase stimulator praliciguat over 12 weeks in patients with heart failure with preserved ejection fraction (CAPACITY HFpEF).
Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES).
Rationale and Design of the VITALITY-HFpEF Trial.
Renal Ca2+ + Mg2+ ATPase in congestive heart failure due to diabetes.
Renal hyporesponsiveness to atrial natriuretic peptide in congestive heart failure results from reduced atrial natriuretic peptide receptor concentrations.
Role of guanylate cyclase modulators in decompensated heart failure.
Role of natriuretic peptide receptor guanylyl cyclase-A in myocardial infarction evaluated using genetically engineered mice.
Safety and efficacy of soluble guanylate cyclase stimulators in patients with heart failure: A systematic review and meta-analysis.
Significant pharmacokinetic and pharmacodynamic interaction of warfarin with the NO-independent sGC activator HMR1766.
Soluble guanylate cyclase activation with cinaciguat: a new approach to the treatment of decompensated heart failure.
Soluble guanylate cyclase modulators in heart failure.
Soluble Guanylate Cyclase Stimulators: a Novel Treatment Option for Heart Failure Associated with Cardiorenal Syndromes?
Soluble guanylate cyclase: a potential therapeutic target for heart failure.
Soluble guanylyl cyclase activation improves progressive cardiac remodeling and failure after myocardial infarction. Cardioprotection over ACE inhibition.
Stimulation of soluble guanylyl cyclase (sGC) by riociguat attenuates heart failure and pathological cardiac remodelling.
Targeting heme-oxidized soluble guanylate cyclase in experimental heart failure.
The efficacy and safety of soluble guanylate cyclase stimulators in patients with heart failure: A systematic review and meta-analysis.
The Role of sGC Stimulators and Activators in Heart Failure With Reduced Ejection Fraction.
Treatment of Heart Failure with Preserved Ejection Fraction.
Uncoupling of atrial natriuretic peptide extraction and cyclic guanosine monophosphate production in the pulmonary circulation in patients with severe heart failure.
Up-regulation of 'clearance' receptors in patients with chronic heart failure: a possible explanation for the resistance to biological effects of cardiac natriuretic hormones.
Updates in pharmacotherapy of heart failure with reduced ejection fraction.
Vericiguat for Heart Failure with Reduced Ejection Fraction.
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction.
Vericiguat in patients with heart failure and reduced ejection fraction.
Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study.
Vericiguat: A Novel Oral Soluble Guanylate Cyclase Stimulator for the Treatment of Heart Failure.
Vericiguat: First Approval.
Volume overload induces differential spatiotemporal regulation of myocardial soluble guanylyl cyclase in eccentric hypertrophy and heart failure.
[Functional activity of platelet guanylate cyclase and cardiac hemodynamics in patients with chronic heart failure and relevant changes after treatment with isosorbide-5-mononitrate]
heme oxygenase (biliverdin-producing) deficiency
Heme oxygenase-1 deficiency leads to alteration of soluble guanylate cyclase redox regulation.
Hepatic Encephalopathy
Activation of soluble guanylate cyclase by nitric oxide in lymphocytes correlates with minimal hepatic encephalopathy in cirrhotic patients.
Hepatitis
Altered modulation of soluble guanylate cyclase by nitric oxide in patients with liver disease.
Altered modulation of soluble guanylate cyclase in lymphocytes from patients with liver disease.
Hepatitis A
Cost-effectiveness analyses of hepatitis A vaccine: a systematic review to explore the effect of methodological quality on the economic attractiveness of vaccination strategies.
Hepatopulmonary Syndrome
Methylene blue improves the hepatopulmonary syndrome.
Hernias, Diaphragmatic, Congenital
Nitric oxide activity through guanylate cyclase and phosphodiesterase modulation is impaired in fetal lambs with congenital diaphragmatic hernia.
The soluble guanylyl cyclase activator BAY 60-2770 potently relaxes the pulmonary artery on congenital diaphragmatic hernia rabbit model.
Herpes Zoster
Development of p-benzoylbenzoylated [N,C,rANP(1-28)]pBNP32 (pBNP1) derivatives and affinity photolabeling of the bovine NPR-A receptor.
Differential regional expression of three natriuretic peptide receptor genes within primate tissues.
Downregulation of adrenal atrial natriuretic peptide receptor mRNAs and proteins by pregnancy in rats.
Phosphorylation of atrial natriuretic factor R1 receptor by serine/threonine protein kinases: evidences for receptor regulation.
Purification and characterization of two types of atrial natriuretic factor receptors from bovine adrenal cortex: guanylate cyclase-linked and cyclase-free receptors.
Tissue distribution and localization of natriuretic peptide receptor subtypes in stroke-prone spontaneously hypertensive rats.
Vascular Endothelial Growth Factors and vascular permeability.
Hyperalgesia
Activation and up-regulation of spinal cord nitric oxide receptor, soluble guanylate cyclase, after formalin injection into the rat hind paw.
Characterization of nociceptin hyperalgesia and allodynia in conscious mice.
Choline attenuates inflammatory hyperalgesia activating nitric oxide/cGMP/ATP-sensitive potassium channels pathway.
Differential effects of intrathecally and intracerebroventricularly administered nitric oxide donors on noxious mechanical and thermal stimulation.
Dual effect of local application of nitric oxide donors in a model of incision pain in rats.
Glycinergic mediation of tactile allodynia induced by platelet-activating factor (PAF) through glutamate-NO-cyclic GMP signalling in spinal cord in mice.
Inhibition of inducible nitric oxide synthase in persistent pain.
Involvement of endogenous nitric oxide in the mechanism of bradykinin-induced peripheral hyperalgesia.
Involvement of glutamate receptors in strychnine- and bicuculline-induced allodynia in conscious mice.
Nitric oxide (NO) and nociceptive processing in the spinal cord.
Nitric oxide mediates allodynia induced by intrathecal administration of prostaglandin E2 or prostaglandin F2 alpha in conscious mice.
Nitric oxide mediates the thermal hyperalgesia produced in a model of neuropathic pain in the rat.
Nitric oxide signaling in pain and nociceptor sensitization in the rat.
NMDAR and JNK Activation in the Spinal Trigeminal Nucleus Caudalis Contributes to Masseter Hyperalgesia Induced by Stress.
NO/cGMP production is important for the endogenous peripheral control of hyperalgesia during inflammation.
Pharmacological evidence for the participation of NO-cyclic GMP-PKG-K(+) channel pathway in the antiallodynic action of resveratrol.
Pharmacological modulation of secondary mediator systems--cyclic AMP and cyclic GMP--on inflammatory hyperalgesia.
Rapid development of nitric oxide-induced hyperalgesia depends on an alternate to the cGMP-mediated pathway in the rat neuropathic pain model.
Superoxide signaling in pain is independent of nitric oxide signaling.
The kappa-opioid agonist (+/-)-bremazocine elicits peripheral antinociception by activation of the L-arginine/nitric oxide/cyclic GMP pathway.
The role of systemic, spinal and supraspinal L-arginine-nitric oxide-cGMP pathway in thermal hyperalgesia caused by intrathecal injection of glutamate in mice.
The ruthenium nitric oxide donor, [Ru(HEDTA)NO], inhibits acute nociception in mice by modulating oxidative stress, cytokine production and activating the cGMP/PKG/ATP-sensitive potassium channel signaling pathway.
TRPA1, NMDA receptors and nitric oxide mediate mechanical hyperalgesia induced by local injection of magnesium sulfate into the rat hind paw.
Hypercalcemia
Constitutively activated receptors for parathyroid hormone and parathyroid hormone-related peptide in Jansen's metaphyseal chondrodysplasia.
Hypercholesterolemia
Effect of hypercholesterolemia on expression and function of vascular soluble guanylyl cyclase.
Hypercholesterolemia is associated with a reduced response of smooth muscle guanylyl cyclase to nitrovasodilators.
The effect of hypercholesterolemia on platelet soluble guanylyl cyclase.
Hyperemia
Arginine analogues inhibit responses mediated by ATP-sensitive K+ channels.
Changes in guanylate cyclase activity in arteriolar smooth muscle cells and hemodynamics after ischemia-reperfusion in rats.
Hydrogen Peroxide-Dependent Arteriolar Dilation in Contracting Muscle of Rats Fed Normal and High Salt Diets.
[Role of the endothelium in the development of reactive hyperemia]
[The participation of humoral factors released by the endothelium in the development of reactive hyperemia]
Hyperglycemia
Effect of elevated glucose on cyclic GMP and eicosanoids produced by porcine aortic endothelium.
Endothelium-dependent inhibition of Na(+)-K+ ATPase activity in rabbit aorta by hyperglycemia. Possible role of endothelium-derived nitric oxide.
Hyperkalemia
Soluble Guanylate Cyclase Stimulators: a Novel Treatment Option for Heart Failure Associated with Cardiorenal Syndromes?
Hyperlipidemias
Mechanisms underlying dysfunction of carotid arteries in genetically hyperlipidemic rabbits.
Hyperopia
A novel mutation in the GUCY2D gene responsible for an early onset severe RP different from the usual GUCY2D-LCA phenotype.
Hypersensitivity
Distinct functions of soluble guanylyl cyclase isoforms NO-GC1 and NO-GC2 in inflammatory and neuropathic pain processing.
Emerging receptor target in the pharmacotherapy of irritable bowel syndrome with constipation.
Pharmacological assessments of nitric oxide synthase isoforms and downstream diversity of NO signaling in the maintenance of thermal and mechanical hypersensitivity after peripheral nerve injury in mice.
Role of soluble guanylate cyclase in the trigeminal subnucleus caudalis in capsaicin-induced muscle hypersensitivity.
Role of the haeme oxygenase/carbon monoxide pathway in mechanical nociceptor hypersensitivity.
Spinal nNOS activation mediates sigma-1 receptor-induced mechanical and thermal hypersensitivity in mice: involvement of PKC-dependent NR1 phosphorylation.
Hypertension
A Bayesian network meta-analysis on the efficacy and safety of eighteen targeted drugs or drug combinations for pulmonary arterial hypertension.
A novel approach for the treatment of hypertension with the soluble guanylate cyclase stimulating drug.
A-type natriuretic peptide receptor in the spontaneously hypertensive rat kidney.
Acute effects of riociguat in borderline or manifest pulmonary hypertension associated with chronic obstructive pulmonary disease.
Aging and chronic hypertension decrease expression of rat aortic soluble guanylyl cyclase.
Alteration of the soluble guanylate cyclase system in the vascular wall of lead-induced hypertension in rats.
Alterations of the vascular and the myocardial guanylate cyclase/cGMP-system induced by long-term hypertension in rats.
Altered expression of vascular natriuretic peptide receptors in experimental hypertensive rats.
Altered regulation of renal nitric oxide and atrial natriuretic peptide systems in angiotensin II-induced hypertension.
Alternative splicing of cGMP-dependent protein kinase I in angiotensin-hypertension: novel mechanism for nitrate tolerance in vascular smooth muscle.
An exploratory, randomised, placebo-controlled, 14 day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertension.
Androgen-sensitive hypertension associated with soluble guanylate cyclase-?1 deficiency is mediated by 20-HETE.
Angiotensin II-Induced Hypertension Is Attenuated by Reduction of Sympathetic Output in NO-Sensitive Guanylyl Cyclase 1 Knockout Mice.
Arg13 of B-type natriuretic Peptide reciprocally modulates binding to guanylyl cyclase but not clearance receptors.
Augmented S-nitrosylation contributes to impaired relaxation in angiotensin II hypertensive mouse aorta: role of thioredoxin reductase.
Blockers of the L-arginine-nitric oxide-cyclic GMP pathway facilitate baroreceptor resetting.
CaMKII-mediated increased lusitropic responses to beta-adrenoreceptor stimulation in ANP-receptor deficient mice.
Central role of guanylyl cyclase in natriuretic peptide signaling in hypertension and metabolic syndrome.
Change of right heart size and function by long-term therapy with riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Characterization of the human alpha1 beta1 soluble guanylyl cyclase promoter: key role for NF-kappaB(p50) and CCAAT-binding factors in regulating expression of the nitric oxide receptor.
Comparative Safety of Drugs Targeting the Nitric Oxide Pathway in Pulmonary Hypertension: A Mixed Approach Combining a Meta-analysis of Clinical Trials and a Disproportionality Analysis From the World Health Organization Pharmacovigilance Database.
Comparison of the crystal structures and thermochemistry of a novel soluble guanylate cyclase stimulator riociguat and its solvates.
Contribution of the renin-angiotensin system to subsensitivity of soluble guanylyl cyclase in TGR(mREN2)27 rats.
Crosstalk between central pathways of nitric oxide and carbon monoxide in the hypertensive action of cyclosporine.
Differences between natriuretic peptide receptors in the olfactory bulb and hypothalamus from spontaneously hypertensive and normotensive rat brain.
Differentially-altered vascular guanylate cyclase isoforms in experimental hypertensive rats.
Downregulation of soluble guanylyl cyclase in young and aging spontaneously hypertensive rats.
Effect of methylene blue on blood pressure in rats.
Effect of renal injury-induced neurogenic hypertension on NO synthase, caveolin-1, AKt, calmodulin and soluble guanylate cyclase expressions in the kidney.
Effects of age and sex on the pharmacokinetics of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521).
Effects of Sevoflurane on Hemodynamics and Inducible Nitric Oxide Synthase/Soluble Guanylate Cyclase Signaling Pathway in a Rat Model of Pulmonary Arterial Hypertension.
Effects of the JNK inhibitor anthra[1,9-cd]pyrazol-6(2H)-one (SP-600125) on soluble guanylyl cyclase alpha1 gene regulation and cGMP synthesis.
Efficacy and safety of riociguat in combination therapy for patients with pulmonary arterial hypertension (PATENT studies).
Efficacy and safety of riociguat in the treatment of chronic thromboembolic pulmonary arterial hypertension: A meta-analysis.
Endothelium-derived vasoactive factors and hypertension: possible roles in pathogenesis and as treatment targets.
Evaluation of heterodimeric guanylyl cyclase genes as candidates for human hypertension.
Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension.
Fatal gastrointestinal obstruction and hypertension in mice lacking nitric oxide-sensitive guanylyl cyclase.
First-in-child use of the oral soluble guanylate cyclase stimulator riociguat in pulmonary arterial hypertension.
Gender-specific hypertension and responsiveness to nitric oxide in sGCalpha1 knockout mice.
Gene expression of brain nitric oxide synthase and soluble guanylyl cyclase in hypothalamus and medulla of two-kidney, one clip hypertensive rats.
Gene expression of natriuretic peptide receptors in rats with DOCA-salt hypertension.
Gene transfer of neuronal nitric oxide synthase into intracardiac Ganglia reverses vagal impairment in hypertensive rats.
Genetic mapping of soluble guanylyl cyclase genes: implications for linkage to blood pressure in the Dahl rat.
Genetic modifiers of hypertension in soluble guanylate cyclase ?1-deficient mice.
Human-antigen R (HuR) expression in hypertension: downregulation of the mRNA stabilizing protein HuR in genetic hypertension.
Hypertension reduces soluble guanylyl cyclase expression in the mouse aorta via the Notch signaling pathway.
Hypervolemic hypertension in mice with systemic inactivation of the (floxed) guanylyl cyclase-A gene by alphaMHC-Cre-mediated recombination.
Impairment of endothelium-dependent relaxation and changes in levels of cyclic GMP in carotid arteries from stroke-prone spontaneously hypertensive rats.
Improving Survival in Patients with Pulmonary Arterial Hypertension: Focus on Intravenous Epoprostenol.
In vitro-in vivo correlation of the drug-drug interaction potential of antiretroviral HIV treatment regimens on CYP1A1 substrate riociguat.
In vitroand in vivo investigation of metabolic fate of riociguat by HPLC-Q-TOF/MS/MS and in silico evaluation of the metabolites by ADMET predictor™.
Individual dose adjustment of riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
KMUP-1 inhibits hypertension-induced left ventricular hypertrophy through regulation of nitric oxide synthases, ERK1/2, and calcineurin.
Lead-induced hypertension: role of oxidative stress.
Left but not right cardiac hypertrophy in atrial natriuretic peptide receptor-deficient mice is prevented by angiotensin type 1 receptor antagonist losartan.
Long-term blood pressure lowering and cGMP-activating actions of the novel ANP analog MANP.
M-atrial natriuretic peptide and nitroglycerin in a canine model of experimental acute hypertensive heart failure: differential actions of 2 cGMP activating therapeutics.
Magnetic resonance imaging accurately estimates LV mass in a transgenic mouse model of cardiac hypertrophy.
MLK3 mediates impact of PKG1? on cardiac function and controls blood pressure through separate mechanisms.
Molecular dissection of mouse soluble guanylyl cyclase alpha1 promoter.
Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions.
Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models.
NO-sensitive guanylyl cyclase in the lung.
Participation of nitric oxide and N-methyl-D-aspartic acid receptors in the pressor response to intrathecal injected noradrenaline at the spinal cord of the rat.
Pharmacokinetic interaction of riociguat and antiretroviral combination regimens in HIV-1-infected adults.
Pharmacokinetic interaction profile of riociguat, a new soluble guanylate cyclase stimulator, in vitro.
Phosphodiesterase 5 attenuates the vasodilatory response in renovascular hypertension.
Phosphodiesterase type 5 inhibitor to riociguat transition is associated with hemodynamic and symptomatic improvement in pulmonary hypertension.
Phosphorylation of atrial natriuretic factor R1 receptor by serine/threonine protein kinases: evidences for receptor regulation.
Plasma atrial natriuretic peptide and natriuretic peptide receptor gene expression in adipose tissue of normotensive and hypertensive obese patients.
Pulmonary Hypertension in Adults with Congenital Heart Disease: Real-World Data from the International COMPERA-CHD Registry.
Redox Mechanisms Influencing cGMP Signaling in Pulmonary Vascular Physiology and Pathophysiology.
Renal atrial natriuretic peptide receptors binding properties and function are resistant to DOCA-salt-induced hypertension in rats.
Renal Soluble Guanylate Cyclase Is Downregulated in Sunitinib-Induced Hypertension.
Reversal of severe angioproliferative pulmonary arterial hypertension and right ventricular hypertrophy by combined phosphodiesterase-5 and endothelin receptor inhibition.
Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study).
Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study.
Riociguat for the treatment of pulmonary arterial hypertension.
Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2).
Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry.
Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry.
Riociguat, a soluble guanylate cyclase stimulator, ameliorates right ventricular contraction in pulmonary arterial hypertension.
Riociguat: a novel new drug for treatment of pulmonary hypertension.
Riociguat: a review of its use in patients with chronic thromboembolic pulmonary hypertension or pulmonary arterial hypertension.
Riociguat: Clinical research and evolving role in therapy.
Riociguat: first global approval.
Roles of heme oxygenase/carbon monoxide system in genetically hypertensive rats.
Salt-resistant hypertension in mice lacking the guanylyl cyclase-A receptor for atrial natriuretic peptide.
Sick vessel syndrome: vascular changes in hypertension and atherosclerosis.
Smooth muscle-specific deletion of nitric oxide-sensitive guanylyl cyclase is sufficient to induce hypertension in mice.
Soluble guanylate cyclase contribute genetic susceptibility to essential hypertension in the Han Chinese population.
Soluble guanylate cyclase stimulation on cardiovascular remodeling in angiotensin II-induced hypertensive rats.
Soluble guanylate cyclase stimulator reduced the gastrointestinal fibrosis in bleomycin-induced mouse model of systemic sclerosis.
Soluble guanylate cyclase stimulator, trans-4-methoxy-?-nitrostyrene, has a beneficial effect in monocrotaline-induced pulmonary arterial hypertension in rats.
Soluble guanylate cyclase stimulators for the treatment of hypertension: Discovery of MK-2947.
Soluble guanylate cyclase: a new therapeutic target for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Stimulation of soluble guanylate cyclase diminishes intrauterine growth restriction in a rat model of placental ischemia.
Switching from sildenafil to riociguat for the treatment of PAH and inoperable CTEPH: Real-life experiences.
Systemic Sclerosis and Systemic Lupus Erythematosus Overlap Syndrome with Pulmonary Arterial Hypertension Successfully Treated with Immunosuppressive Therapy and Riociguat.
Targeting soluble guanylate cyclase for the treatment of pulmonary hypertension.
The guanylyl cyclase-deficient mouse defines differential pathways of natriuretic peptide signaling.
The Soluble Guanylate Cyclase Stimulator Riociguat Ameliorates Pulmonary Hypertension Induced by Hypoxia and SU5416 in Rats.
The soluble guanylate cyclase stimulator, 1-nitro-2-phenylethane, reverses monocrotaline-induced pulmonary arterial hypertension in rats.
The titerless infected-cells preservation and scale-up (TIPS) method for large-scale production of NO-sensitive human soluble guanylate cyclase (sGC) from insect cells infected with recombinant baculovirus.
Treatment Selection in Pulmonary Arterial Hypertension: Phosphodiesterase Type 5 Inhibitors versus Soluble Guanylate Cyclase Stimulator.
Ventricular arrhythmias, increased cardiac calmodulin kinase II expression, and altered repolarization kinetics in ANP receptor deficient mice.
YC-1 attenuates hypoxia-induced pulmonary arterial hypertension in mice.
YC-1 reduces placental sFlt-1 and soluble endoglin production and decreases endothelial dysfunction: A possible therapeutic for preeclampsia.
[Cellular signalling pathways and pathophysiology of pulmonary arterial hypertension.]
[Diagnosis and treatment of pulmonary hypertension].
[Doxazosin and soluble guanylate cyclase in a rat model of hypertension]
[The achievements of the modern specific therapy of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: focus on the stimulator of soluble guanylate cyclase riociguat].
Hypertension, Portal
Soluble guanylyl cyclase stimulation and phosphodiesterase-5 inhibition improve portal hypertension and reduce liver fibrosis in bile duct-ligated rats.
Hypertension, Pregnancy-Induced
Impaired guanosine 3',5'-cyclic phosphate production in severe pregnancy-induced hypertension with high plasma levels of atrial and brain natriuretic peptides.
Hypertension, Pulmonary
Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling.
Acute effects of riociguat in borderline or manifest pulmonary hypertension associated with chronic obstructive pulmonary disease.
Acute Hemodynamic Effects of Riociguat in Patients with Pulmonary Hypertension Associated with Diastolic Heart Failure (DILATE-1): A Randomized, Double-Blind, Placebo-Controlled, Single-Dose Study.
Analysis of responses to the Rho-kinase Inhibitor Y-27632 in the Pulmonary and Systemic Vascular Bed of the Rat.
Assessment of the effects of hepatic impairment and smoking on the pharmacokinetics of a single oral dose of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521).
Assessment of the effects of renal impairment and smoking on the pharmacokinetics of a single oral dose of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521).
Atrial natriuretic peptide in hypoxia.
Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension.
BAY 41-2272 inhibits the development of chronic hypoxic pulmonary hypertension in rats.
BAY 41-2272, a Direct Activator of Soluble Guanylate Cyclase, Reduces Right Ventricular Hypertrophy and Prevents Pulmonary Vascular Remodeling during Chronic Hypoxia in Neonatal Rats.
Beneficial effects of phosphodiesterase 5 inhibition in pulmonary hypertension are influenced by natriuretic Peptide activity.
cGMP: transition from bench to bedside: a report of the 6th International Conference on cGMP Generators, Effectors and Therapeutic Implications.
Change of right heart size and function by long-term therapy with riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Chronic intratracheal application of the soluble guanylyl cyclase stimulator BAY 41-8543 ameliorates experimental pulmonary hypertension.
Cigarette Smoke-Induced Emphysema and Pulmonary Hypertension Can Be Prevented by Phosphodiesterase 4 and 5 Inhibition in Mice.
Cinaciguat, a Soluble Guanylate Cyclase Activator, Augments cGMP after Oxidative Stress and Causes Pulmonary Vasodilation in Neonatal Pulmonary Hypertension.
Cinaciguat, a soluble guanylate cyclase activator, causes potent and sustained pulmonary vasodilation in the ovine fetus.
Clinical Significance of Guanylate Cyclase Stimulator, Riociguat, on Right Ventricular Functional Improvement in Patients with Pulmonary Hypertension.
Clinically Worsening Chronic Thromboembolic Pulmonary Hypertension by Riociguat After Balloon Pulmonary Angioplasty.
Computational exploration of the binding mode of heme-dependent stimulators into the active catalytic domain of soluble guanylate cyclase.
Dehydroepiandrosterone upregulates soluble guanylate cyclase and inhibits hypoxic pulmonary hypertension.
Determination of riociguat and its major human metabolite M-1 in human plasma by stable-isotope dilution LCMS/MS.
Development of the normal and hypertensive pulmonary vasculature.
Discovery of CYR715: A novel carboxylic acid-containing soluble guanylate cyclase stimulator.
Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension.
Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure.
Effect of BAY 41-2272 in the pulmonary hypertension induced by heparin-protamine complex in anaesthetized dogs.
Effects of age and sex on the pharmacokinetics of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521).
Effects of omeprazole and aluminum hydroxide/magnesium hydroxide on riociguat absorption.
Efficacy and safety of riociguat in the treatment of chronic thromboembolic pulmonary arterial hypertension: A meta-analysis.
Exposure of mice to chronic hypoxia attenuates pulmonary arterial contractile responses to acute hypoxia by increases in extracellular hydrogen peroxide.
First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension.
Guanylate cyclase stimulators for pulmonary hypertension.
In vitroand in vivo investigation of metabolic fate of riociguat by HPLC-Q-TOF/MS/MS and in silico evaluation of the metabolites by ADMET predictor™.
In vivo attenuation of endothelium-dependent pulmonary vasodilation by methylene blue.
Increased hydrogen peroxide downregulates soluble guanylate cyclase in the lungs of lambs with persistent pulmonary hypertension of the newborn.
Individual dose adjustment of riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Inhaled nitric oxide decreases pulmonary soluble guanylate cyclase protein levels in 1-month-old lambs.
Inhaled sGC Modulator Can Lower PH in Patients With COPD Without Deteriorating Oxygenation.
Interfacial residues promote an optimal alignment of the catalytic center in human soluble guanylate cyclase: heterodimerization is required but not sufficient for activity.
Medical management of chronic thromboembolic pulmonary hypertension.
Medical Therapy in Chronic Thromboembolic Pulmonary Hypertension.
Metabolic Syndrome Mediates ROS-miR-193b-NFYA-Dependent Downregulation of Soluble Guanylate Cyclase and Contributes to Exercise-Induced Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction.
Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models.
Novel approaches to the pharmacotherapy of pulmonary arterial hypertension.
Operability assessment in CTEPH: Lessons from the CHEST-1 study.
Pediatric Cardiac Intensive Care Society 2014 Consensus Statement: Pharmacotherapies in Cardiac Critical Care Pulmonary Hypertension.
Pharmacokinetic interaction of riociguat with ketoconazole, clarithromycin, and midazolam.
Pharmacokinetic interaction profile of riociguat, a new soluble guanylate cyclase stimulator, in vitro.
Pharmacokinetic interaction study between riociguat and the combined oral contraceptives levonorgestrel and ethinylestradiol in healthy postmenopausal women.
Pharmacological therapy for patients with chronic thromboembolic pulmonary hypertension.
Phosphodiesterase type 5 inhibitor to riociguat transition is associated with hemodynamic and symptomatic improvement in pulmonary hypertension.
Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: data from the CHEST-2 open-label, randomised, long-term extension trial.
Pulmonary hypertension alters soluble guanylate cyclase activity and expression in pulmonary arteries isolated from fetal lambs.
Redox regulation of responses to hypoxia and NO-cGMP signaling in pulmonary vascular pathophysiology.
Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study).
Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study.
Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial.
Riociguat for patients with chronic thromboembolic pulmonary hypertension: Usefulness of transitioning from phosphodiesterase type 5 inhibitor.
Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study.
Riociguat for the treatment of chronic thromboembolic pulmonary hypertension.
Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2).
Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry.
Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry.
Riociguat, a soluble guanylate cyclase stimulator, ameliorates right ventricular contraction in pulmonary arterial hypertension.
Riociguat, an oral soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension.
Riociguat: a review of its use in patients with chronic thromboembolic pulmonary hypertension or pulmonary arterial hypertension.
Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension.
Riociguat: Clinical research and evolving role in therapy.
Riociguat: first global approval.
sGC and PDE5 are elevated in lambs with increased pulmonary blood flow and pulmonary hypertension.
Soluble guanylate cyclase activator reverses acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs.
Soluble guanylate cyclase agonists inhibit expression and procoagulant activity of tissue factor.
Soluble guanylate cyclase stimulation: an emerging option in pulmonary hypertension therapy.
Soluble guanylate cyclase stimulator riociguat and phosphodiesterase 5 inhibitor sildenafil ameliorate pulmonary hypertension due to left heart disease in mice.
Soluble Guanylate Cyclase Stimulators and Activators.
Soluble Guanylate Cyclase Stimulators in Pulmonary Hypertension.
Soluble guanylate cyclase: a new therapeutic target for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Stimulation of nitric oxide-sensitive soluble guanylate cyclase in monocrotaline-induced pulmonary hypertensive rats.
Stimulation of soluble guanylate cyclase prevents cigarette smoke-induced pulmonary hypertension and emphysema.
Switching from sildenafil to riociguat for the treatment of PAH and inoperable CTEPH: Real-life experiences.
Targeting soluble guanylate cyclase for the treatment of pulmonary hypertension.
The effect of Riociguat on cardiovascular function and efficiency in healthy, juvenile pigs.
The Endothelium-Dependent Nitric Oxide-cGMP Pathway.
The role of pulmonary arterial hypertension-targeted therapy in systemic sclerosis.
The soluble guanylate cyclase activator HMR1766 reverses hypoxia-induced experimental pulmonary hypertension in mice.
The Soluble Guanylate Cyclase Stimulator Riociguat Ameliorates Pulmonary Hypertension Induced by Hypoxia and SU5416 in Rats.
There is no substitute for experience: Lessons learned from CHEST-1 (Chronic Thromboembolic Pulmonary Hypertension Soluble Guanylate Cyclase Stimulator Trial-1) for future clinical trial design.
Treatment of pulmonary hypertension.
Upregulation of lung soluble guanylate cyclase during chronic hypoxia is prevented by deletion of eNOS.
Urodilatin, a natriuretic peptide stimulating particulate guanylate cyclase, and the phosphodiesterase 5 inhibitor dipyridamole attenuate experimental pulmonary hypertension: synergism upon coapplication.
Use of responder threshold criteria to evaluate the response to treatment in the phase III CHEST-1 study.
[Expression of PAI-2 mRNA in peripheral blood leucocytes and regulation by sGC activator in pulmonary hypertension].
[Study on soluble guanylate cyclase in pulmonary hypertension rat model]
[The achievements of the modern specific therapy of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: focus on the stimulator of soluble guanylate cyclase riociguat].
[The soluble guanylate cyclase stimulator riociguat is the first-line therapy for chronic thromboembolic pulmonary hypertension patients].
Hypertension, Renovascular
Natriuretic peptides buffer renin-dependent hypertension.
Phosphodiesterase 5 attenuates the vasodilatory response in renovascular hypertension.
Hyperthyroidism
Altered role of C-type natriuretic peptide-activated pGC-cGMP-PDE3-cAMP signaling in hyperthyroid beating rabbit atria.
Hypertrophy, Left Ventricular
B-type natriuretic peptide receptors in hypertrophied adult rat cardiomyocytes.
Comparison of the Reverse-Remodeling Effect of Pharmacological Soluble Guanylate Cyclase Activation With Pressure Unloading in Pathological Myocardial Left Ventricular Hypertrophy.
Increased guanylate cyclase activity is associated with an increase in cyclic guanosine 3',5'-monophosphate in left ventricular hypertrophy.
Pacing-induced cardiac failure of hypertrophic hearts: effects of cyclic GMP reduction.
Positive inotropy due to lowering cyclic GMP is also mediated by increases in cyclic AMP in control and hypertrophic hearts.
Targeted disruption of the gene for natriuretic peptide receptor-A worsens hypoxia-induced cardiac hypertrophy.
Hypertrophy, Right Ventricular
BAY 41-2272, a Direct Activator of Soluble Guanylate Cyclase, Reduces Right Ventricular Hypertrophy and Prevents Pulmonary Vascular Remodeling during Chronic Hypoxia in Neonatal Rats.
Buffered l-ascorbic acid, alone or bound to KMUP-1 or sildenafil, reduces vascular endothelium growth factor and restores endothelium nitric oxide synthase in hypoxic pulmonary artery.
Targeted disruption of the gene for natriuretic peptide receptor-A worsens hypoxia-induced cardiac hypertrophy.
The effects of cyclic guanylate cyclase stimulation on right ventricular hypertrophy and failure alone and in combination with phosphodiesterase-5 inhibition.
The xanthine derivative KMUP-1 inhibits models of pulmonary artery hypertension via increased NO and cGMP-dependent inhibition of RhoA/Rho kinase.
Hypoglycemia
Hypothalamic S-nitrosylation contributes to the counter-regulatory response impairment following recurrent hypoglycemia.
Hypotension
A novel soluble guanylate cyclase activator with reduced risk of hypotension by short-acting vasodilation.
Cinaciguat, a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure.
Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes.
Contribution of iNOS/sGC/PKG pathway, COX-2, CYP4A1, and gp91(phox) to the protective effect of 5,14-HEDGE, a 20-HETE mimetic, against vasodilation, hypotension, tachycardia, and inflammation in a rat model of septic shock.
CRRL269.
Cyclosporine counteracts endotoxemia-evoked reductions in blood pressure and cardiac autonomic dysfunction via central sGC/MAPKs signaling in rats.
Effects of methylene blue on oxygen availability and regional blood flow during endotoxic shock.
Enhanced Hemeoxygenase Activity in the Rostral Ventrolateral Medulla Mediates the Exaggerated Hemin-Evoked Hypotension in the SHR.
Inhibition of and sensitization to the lethal effects of tumor necrosis factor.
Late, but not early, inhibition of soluble guanylate cyclase decreases mortality in a rat sepsis model.
Mechanisms of atrial natriuretic factor-induced vasodilation.
Methylene blue and vasoplegia: who, when, and how?
Methylene blue reverses endotoxin-induced hypotension.
Methylene blue treatment for cytokine release syndrome-associated vasoplegia following a renal transplant with rATG infusion: A case report and literature review.
Methylene blue: potential use of an antique molecule in vasoplegic syndrome during cardiac surgery.
Modulation of cyclic guanosine monophosphate production during Escherichia coli septic shock.
N(G)-nitro-L-arginine methyl ester, but not methylene blue, attenuates anaphylactic hypotension in anesthetized mice.
Ophidian envenomation strategies and the role of purines.
Protection against TNF-induced lethal shock by soluble guanylate cyclase inhibition requires functional inducible nitric oxide synthase.
The hemodynamic effects of methylene blue when administered at the onset of cardiopulmonary bypass.
The mast cell.
Vasorelaxation induced by a new naphthoquinone-oxime is mediated by NO-sGC-cGMP pathway.
[Does nitric oxide stress exist?]
Ileus
Effect of inhibition of inducible nitric oxide synthase and guanylyl cyclase on endotoxin-induced delay in gastric emptying and intestinal transit in mice.
Jejunal cholinergic, nitrergic, and soluble guanylate cyclase activity in postoperative ileus.
Infections
Arabidopsis thaliana resistance to fusarium oxysporum 2 implicates tyrosine-sulfated peptide signaling in susceptibility and resistance to root infection.
Dirofilaria immitis: heartworm infection alters pulmonary artery endothelial cell behavior.
Ectopic expression of guanylyl cyclase C and endogenous ligand guanylin correlates significantly with Helicobacter pylori infection in gastric carcinogenesis.
Evolutionarily distant pathogens require the Arabidopsis phytosulfokine signalling pathway to establish disease.
Identification of a Hippeastrum hybridum guanylyl cyclase responsive to wounding and pathogen infection.
Pharmacokinetic interaction of riociguat and antiretroviral combination regimens in HIV-1-infected adults.
Pyridopyrimidine derivatives as inhibitors of cyclic nucleotide synthesis: Application for treatment of diarrhea.
Role of Porcine Aminopeptidase N and Sialic Acids in Porcine Coronavirus Infections in Primary Porcine Enterocytes.
The tyrosine-sulfated peptide receptors PSKR1 and PSY1R modify the immunity of Arabidopsis to biotrophic and necrotrophic pathogens in an antagonistic manner.
Urinary nitric oxide synthase activity and cyclic GMP levels are decreased with interstitial cystitis and increased with urinary tract infections.
Infertility
Preserved fertility despite erectile dysfunction in mice lacking the nitric oxide receptor.
Infertility, Female
Guanylate cyclase activity and sperm function.
Inflammatory Bowel Diseases
Emerging treatments in Neurogastroenterology: Perspectives of guanylyl cyclase C agonists use in functional gastrointestinal disorders and inflammatory bowel diseases.
Gut-associated cGMP mediates colitis and dysbiosis in a mouse model of an activating mutation in GUCY2C.
Influence of soluble guanylate cyclase inhibition on inflammation and motility disturbances in DSS-induced colitis.
Lineage-specific T-cell responses to cancer mucosa antigen oppose systemic metastases without mucosal inflammatory disease.
Insulin Resistance
? Cell-specific deletion of guanylyl cyclase A, the receptor for atrial natriuretic peptide, accelerates obesity-induced glucose intolerance in mice.
Decreased cyclic guanosine 3',5' monophosphate and guanylate cyclase activity in leprechaunism: evidence for a postreceptor defect.
Dogfish glucagon analogues counter hyperglycaemia and enhance both insulin secretion and action in diet-induced obese diabetic mice.
Hepatic guanylyl cyclase inhibition induces HISS-dependent insulin resistance.
Omentin changes following bariatric surgery and predictive links with biomarkers for risk of cardiovascular disease.
The Importance of Natriuretic Peptides in Cardiometabolic Diseases.
Insulinoma
Dominant negative mutants of nitric oxide-sensitive guanylyl cyclase.
L-arginine stimulates cyclic guanosine 3',5'-monophosphate formation in rat islets of Langerhans and RINm5F insulinoma cells: evidence for L-arginine:nitric oxide synthase.
Modulation of the cGMP signaling pathway by melatonin in pancreatic beta-cells.
Intestinal Neoplasms
Lineage-specific T-cell responses to cancer mucosa antigen oppose systemic metastases without mucosal inflammatory disease.
Irritable Bowel Syndrome
A comparison of linaclotide and lubiprostone dosing regimens on ion transport responses in human colonic mucosa.
Linaclotide activates guanylate cyclase-C/cGMP/protein kinase-II-dependent trafficking of CFTR in the intestine.
Linaclotide, a new direction in the treatment of irritable bowel syndrome and chronic constipation.
Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit.
Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation.
Randomised clinical trial: linaclotide vs placebo-a study of bi-directional gut and brain axis.
UK clinical experience up to 52?weeks with linaclotide for irritable bowel syndrome with constipation.
Keratoconus
CRB1 GENE MUTATIONS ARE ASSOCIATED WITH KERATOCONUS IN PATIENTS WITH LEBER CONGENITAL AMAUROSIS.
Kidney Diseases
Effects of the Soluble Guanylate Cyclase Stimulator Praliciguat in Diabetic Kidney Disease: A Randomized Placebo-Controlled Clinical Trial.
Kidney Failure, Chronic
Chronic Activation of Heme Free Guanylate Cyclase Leads to Renal Protection in Dahl Salt-Sensitive Rats.
Effects of chronic renal failure on caveolin-1, guanylate cyclase and AKT protein expression.
Medullar expression of type-A natriuretic peptide receptor in an animal model of hypertension induced by renal mass ablation.
Leber Congenital Amaurosis
A nonsense mutation in the retinal specific guanylate cyclase gene is the cause of Leber congenital amaurosis in a large inbred kindred from Jordan.
A novel mutation in the GUCY2D gene responsible for an early onset severe RP different from the usual GUCY2D-LCA phenotype.
AAV-mediated gene therapy in the guanylate cyclase (RetGC1/RetGC2) double knockout mouse model of Leber congenital amaurosis.
Activation of retinal guanylyl cyclase RetGC1 by GCAP1: stoichiometry of binding and effect of new LCA-related mutations.
Complete abolition of the retinal-specific guanylyl cyclase (retGC-1) catalytic ability consistently leads to leber congenital amaurosis (LCA).
Determining consequences of retinal membrane guanylyl cyclase (RetGC1) deficiency in human Leber congenital amaurosis en route to therapy: residual cone-photoreceptor vision correlates with biochemical properties of the mutants.
Different functional outcome of RetGC1 and RPE65 gene mutations in Leber congenital amaurosis.
Evaluating the Role of Retinal Membrane Guanylyl Cyclase 1 (RetGC1) Domains in Binding Guanylyl Cyclase-activating Proteins (GCAPs).
Evidence of a founder effect for the RETGC1 (GUCY2D) 2943DelG mutation in Leber congenital amaurosis pedigrees of Finnish origin.
Factors that affect regulation of cGMP synthesis in vertebrate photoreceptors and their genetic link to human retinal degeneration.
Functional analyses of mutant recessive GUCY2D alleles identified in Leber congenital amaurosis patients: protein domain comparisons and dominant negative effects.
Genetic analysis of the guanylate cyclase activator 1B (GUCA1B) gene in patients with autosomal dominant retinal dystrophies.
Insights gained from gene therapy in animal models of retGC1 deficiency.
Insights into the role of RD3 in guanylate cyclase trafficking, photoreceptor degeneration, and Leber congenital amaurosis.
Photoreceptor Guanylate Cyclase (GUCY2D) Mutations Cause Retinal Dystrophies by Severe Malfunction of Ca2+-Dependent Cyclic GMP Synthesis.
RD3 gene delivery restores guanylate cyclase localization and rescues photoreceptors in the Rd3 mouse model of Leber congenital amaurosis 12.
RD3, the protein associated with Leber congenital amaurosis type 12, is required for guanylate cyclase trafficking in photoreceptor cells.
Regulation of cGMP synthesis in photoreceptors: role in signal transduction and congenital diseases of the retina.
Variants at codon 838 in the GUCY2D gene result in different phenotypes of cone rod dystrophy.
Leukemia
Particulate ANP-sensitive guanylyl cyclase in blood and bone marrow cells of patients with acute leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Adenylate cyclase and guanylate cyclase activity in normal and leukemic human lymphocytes.
Leukemia, Myeloid, Acute
Particulate ANP-sensitive guanylyl cyclase in blood and bone marrow cells of patients with acute leukemia.
Liver Cirrhosis
Activation of soluble guanylate cyclase by nitric oxide in lymphocytes correlates with minimal hepatic encephalopathy in cirrhotic patients.
Brain regional alterations in the modulation of the glutamate-nitric oxide-cGMP pathway in liver cirrhosis. Role of hyperammonemia and cell types involved.
Cyclic GMP pathways in hepatic encephalopathy. Neurological and therapeutic implications.
Neurons exposed to ammonia reproduce the differential alteration in nitric oxide modulation of guanylate cyclase in the cerebellum and cortex of patients with liver cirrhosis.
Nitric oxide-independent activation of soluble guanylate cyclase by BAY 60-2770 in experimental liver fibrosis.
Single-Cell Transcriptomic Analysis Reveals a Hepatic Stellate Cell-Activation Roadmap and Myofibroblast Origin During Liver Fibrosis in Mice.
Soluble guanylyl cyclase stimulation and phosphodiesterase-5 inhibition improve portal hypertension and reduce liver fibrosis in bile duct-ligated rats.
Liver Cirrhosis, Biliary
Vasodilatory responses of isolated arteries of cirrhotic rats.
Liver Diseases
Activation of soluble guanylate cyclase by nitric oxide in lymphocytes correlates with minimal hepatic encephalopathy in cirrhotic patients.
Alterations in soluble guanylate cyclase content and modulation by nitric oxide in liver disease.
Altered modulation of soluble guanylate cyclase by nitric oxide in patients with liver disease.
Altered modulation of soluble guanylate cyclase in lymphocytes from patients with liver disease.
Hepatic guanylate cyclase activity is decreased in a model of cirrhosis: a quantitative cytochemistry study.
sGC stimulator praliciguat suppresses stellate cell fibrotic transformation and inhibits fibrosis and inflammation in models of NASH.
Liver Failure
Altered content and modulation of soluble guanylate cyclase in the cerebellum of rats with portacaval anastomosis.
Region selective alterations of soluble guanylate cyclase content and modulation in brain of cirrhotic patients.
Liver Failure, Acute
Evidence of increased guanylate cyclase activation by acetylcysteine in fulminant hepatic failure.
In vivo evidence of enhanced guanylyl cyclase activation during the hyperdynamic circulation of acute liver failure.
Lordosis
A potential role of cyclic GMP in the regulation of lordosis behavior of female rats.
Evidence that the effect of melanocortins on female sexual behavior in preoptic area is mediated by the MC3 receptor; Participation of nitric oxide.
Regulation of soluble guanylyl cyclase activity by oestradiol and progesterone in the hypothalamus but not hippocampus of female rats.
The nitric oxide pathway participates in estrous behavior induced by progesterone and some of its ring A-reduced metabolites.
The nitric oxide pathway participates in lordosis behavior induced by central administration of leptin.
Lung Diseases
Therapeutic potential of soluble guanylate cyclase modulators in neonatal chronic lung disease.
Lung Diseases, Interstitial
Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial.
The role of pulmonary arterial hypertension-targeted therapy in systemic sclerosis.
Lung Injury
Guanylyl Cyclase Activation Reverses Resistive Breathing-induced Lung Injury and Inflammation.
Is nitric oxide released in oleic acid lung injury?
L-arginine-dependent nitric oxide synthase: a new metabolic pathway in the lung and airways.
Novel soluble guanylyl cyclase stimulator BAY 41-2272 attenuates ischemia-reperfusion-induced lung injury.
Opposite effects of ANP receptors in attenuation of LPS-induced endothelial permeability and lung injury.
Soluble guanylyl cyclase expression is reduced in LPS-induced lung injury.
The role of natriuretic peptide receptor-A signaling in unilateral lung ischemia-reperfusion injury in the intact mouse.
Transforming growth factor-beta down-regulates sGC subunit expression in pulmonary artery smooth muscle cells via MEK and ERK signaling.
Lung Neoplasms
Inhibition of non-small cell lung cancer cell migration by grape seed proanthocyanidins is mediated through the inhibition of nitric oxide, guanylate cyclase, and ERK1/2.
Lupus Erythematosus, Systemic
Systemic Sclerosis and Systemic Lupus Erythematosus Overlap Syndrome with Pulmonary Arterial Hypertension Successfully Treated with Immunosuppressive Therapy and Riociguat.
Lymphatic Metastasis
Expression of the intestinal biomarkers Guanylyl cyclase C and CDX2 in poorly differentiated colorectal carcinomas.
Lymphoma
Interferon enhances guanylate cyclase activity in human lymphoma cells.
Particulate ANP-sensitive guanylyl cyclase in blood and bone marrow cells of patients with acute leukemia.
Macular Degeneration
Cone dystrophy or macular dystrophy associated with novel autosomal dominant GUCA1A mutations.
Mutation analysis at codon 838 of the Guanylate Cyclase 2D gene in Spanish families with autosomal dominant cone, cone-rod, and macular dystrophies.
Two retinal dystrophy-associated missense mutations in GUCA1A with distinct molecular properties result in a similar aberrant regulation of the retinal guanylate cyclase.
Malaria
cGMP Signalling: Malarial Guanylyl Cyclase Leads the Way.
Guanylyl cyclase activity associated with putative bifunctional integral membrane proteins in Plasmodium falciparum.
PbGCbeta is essential for Plasmodium ookinete motility to invade midgut cell and for successful completion of parasite life cycle in mosquitoes.
The gametocyte-activating factor xanthurenic acid stimulates an increase in membrane-associated guanylyl cyclase activity in the human malaria parasite Plasmodium falciparum.
Marfan Syndrome
Aortic disease in Marfan syndrome is caused by overactivation of sGC-PRKG signaling by NO.
Meconium Ileus
Meconium ileus caused by mutations in GUCY2C, encoding the CFTR-activating guanylate cyclase 2C.
Melanoma
Differential expression of functional guanylyl cyclases in melanocytes: absence of nitric-oxide-sensitive isoform in metastatic cells.
Photoreceptor proteins as cancer-retina antigens.
Sildenafil Potentiates a cGMP-Dependent Pathway to Promote Melanoma Growth.
Stimulation of cyclic GMP efflux in human melanocytes by hypergravity generated by centrifugal acceleration.
Visible light modulates the expression of cancer-retina antigens.
Melanoma, Experimental
Natriuretic peptide receptor A as a novel target for cancer.
Memory Disorders
Hyperammonemia inhibits the natriuretic peptide receptor 2 (NPR-2)-mediated cyclic GMP synthesis in the astrocytic compartment of rat cerebral cortex slices.
In vivo exposure to carbon monoxide causes delayed impairment of activation of soluble guanylate cyclase by nitric oxide in rat brain cortex and cerebellum.
Mouse knockout of guanylyl cyclase C: Recognition memory deficits in the absence of activity changes.
Metabolic Syndrome
Central role of guanylyl cyclase in natriuretic peptide signaling in hypertension and metabolic syndrome.
Metabolic Syndrome Mediates ROS-miR-193b-NFYA-Dependent Downregulation of Soluble Guanylate Cyclase and Contributes to Exercise-Induced Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction.
Omentin changes following bariatric surgery and predictive links with biomarkers for risk of cardiovascular disease.
Soluble guanylate cyclase (sGC) down-regulation by abnormal extracellular matrix proteins as a novel mechanism in vascular dysfunction: Implications in metabolic syndrome.
Soluble guanylate cyclase chronic stimulation effects on cardiovascular reactivity in cafeteria diet-induced rat model of metabolic syndrome.
Time-of-Day-Dependent Effects of Bromocriptine to Ameliorate Vascular Pathology and Metabolic Syndrome in SHR Rats Held on High Fat Diet.
Migraine Disorders
Carnosine as a regulator of soluble guanylate cyclase.
Soluble guanylyl cyclase is a critical regulator of migraine-associated pain.
MPTP Poisoning
Upregulation of guanylyl cyclase expression and activity in striatum of MPTP-induced parkinsonism in mice.
Multiple Sclerosis
Cerebral and cerebellar guanylate cyclase activities in multiple sclerosis patients.
Reduced expression of NO-sensitive guanylyl cyclase in reactive astrocytes of Alzheimer disease, Creutzfeldt-Jakob disease, and multiple sclerosis brains.
Muscle Spasticity
Supersensitive dilator response to nitroglycerin but not to atrial natriuretic peptide in spastic coronary arteries in coronary spastic angina.
Various pathogenetic factors revolving around the central role of protein kinase C activation in the occurrence of cerebral vasospasm
Muscular Diseases
Involvement of nitric oxide in nicotinic receptor-mediated myopathy.
Muscular Dystrophies
Guanylate cyclase activity in normal and diseased human muscle.
Muscular Dystrophy, Duchenne
Nitric Oxide Regulates Skeletal Muscle Fatigue, Fiber Type, Microtubule Organization, and Mitochondrial ATP Synthesis Efficiency Through cGMP-Dependent Mechanisms.
Mycoses
The Hippeastrum hybridum PepR1 gene (HpPepR1) encodes a functional guanylyl cyclase and is involved in early response to fungal infection.
The tyrosine-sulfated peptide receptors PSKR1 and PSY1R modify the immunity of Arabidopsis to biotrophic and necrotrophic pathogens in an antagonistic manner.
Myocardial Infarction
Atrial natriuretic factor influences in vivo plasma, lung and aortic wall cGMP concentrations differently.
Cardioprotection by ischemic postconditioning and cGMP-elevating agents involves cardiomyocyte nitric oxide-sensitive guanylyl cyclase.
Computational exploration of the binding mode of heme-dependent stimulators into the active catalytic domain of soluble guanylate cyclase.
Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection.
Discovery of new therapeutic redox targets for cardioprotection against ischemia/reperfusion injury and heart failure.
Endothelial dysfunction in chronic myocardial infarction despite increased vascular endothelial nitric oxide synthase and soluble guanylate cyclase expression: role of enhanced vascular superoxide production.
Role of natriuretic peptide receptor guanylyl cyclase-A in myocardial infarction evaluated using genetically engineered mice.
Soluble guanylyl cyclase activation improves progressive cardiac remodeling and failure after myocardial infarction. Cardioprotection over ACE inhibition.
Myocardial Ischemia
Effects of a novel, selective and potent phosphodiesterase type V inhibitor, E4021, on myocardial ischemia in guinea pigs.
Endothelium, coronary vasodilation, and organic nitrates.
Inhibition of nitric oxide synthesis causes myocardial ischemia in endotoxemic rats.
Novel snake venom ligand dendroaspis natriuretic peptide is selective for natriuretic peptide receptor-A in human heart: downregulation of natriuretic peptide receptor-A in heart failure.
Pharmacological activation of soluble guanylate cyclase protects the heart against ischemic injury.
Soluble guanylate cyclase of platelets: function and regulation in normal and pathological states.
Soluble guanylyl cyclase activation improves progressive cardiac remodeling and failure after myocardial infarction. Cardioprotection over ACE inhibition.
[Soluble guanyl cyclase of blood platelets and heart of rats with experimental myocardial ischemia]
[Soluble guanylate cyclase from rat platelets during experimental myocardial ischemia]
Myocarditis
[Comparison of guanylate cyclase activity of the heart and thrombocytes in normal states and in experimental allergic myocarditis]
Myoma
Estrogen receptor in human myoma tissue.
Nasal Polyps
Endothelial nitric oxide synthase/soluble guanylate cyclase system in human nasal polyps.
Enzyme-ultracytochemical study of adenylate and guanylate cyclases in normal and pathologic human nasal mucosa.
Nematode Infections
Evolutionarily distant pathogens require the Arabidopsis phytosulfokine signalling pathway to establish disease.
Neoplasm Metastasis
Association of GUCY2C expression in lymph nodes with time to recurrence and disease-free survival in pN0 colorectal cancer.
Comparison of histopathology and RT-qPCR amplification of guanylyl cyclase C for detection of colon cancer metastases in lymph nodes.
Cytokine adjuvanation of therapeutic anti-tumor immunity targeted to cancer mucosa antigens.
Ectopic expression of guanylyl cyclase C in adenocarcinomas of the esophagus and stomach.
Epitope-targeted cytotoxic T cells mediate lineage-specific antitumor efficacy induced by the cancer mucosa antigen GUCY2C.
Expression of the intestinal biomarkers Guanylyl cyclase C and CDX2 in poorly differentiated colorectal carcinomas.
Guanylyl cyclase C as a biomarker in colorectal cancer.
Guanylyl cyclase C prevents colon cancer metastasis by regulating tumor epithelial cell matrix metalloproteinase-9.
Guanylyl cyclase C-induced immunotherapeutic responses opposing tumor metastases without autoimmunity.
Intrinsic variability in the detection of micrometastases in lymph nodes for re-staging of colorectal cancer. effect of individual markers and tissue samples.
Lineage-specific T-cell responses to cancer mucosa antigen oppose systemic metastases without mucosal inflammatory disease.
Molecular staging of node negative patients with colorectal cancer.
Natriuretic peptide receptor A as a novel target for cancer.
Opportunities for near-infrared thermal ablation of colorectal metastases by guanylyl cyclase C-targeted gold nanoshells.
Use of guanylyl cyclase C for detecting micrometastases in lymph nodes of patients with colon cancer.
[Detection of guanylate cyclase C mRNA and cytokeratin 20 mRNA in peripheral blood and analysis of prognosis in early to moderate colorectal cancer patients].
Neoplasm Micrometastasis
A validated quantitative assay to detect occult micrometastases by reverse transcriptase-polymerase chain reaction of guanylyl cyclase C in patients with colorectal cancer.
Discordant quantitative detection of putative biomarkers in nodal micrometastases of colorectal cancer: biological and clinical implications.
Pathological staging and therapy of oesophageal and gastric cancer.
Use of guanylyl cyclase C for detecting micrometastases in lymph nodes of patients with colon cancer.
Neoplasms
A role for PSK signaling in wounding and microbial interactions in Arabidopsis
A role for PSK signaling in wounding and microbial interactions in Arabidopsis.
Aberrant alternative splicing of thyroid hormone receptor in a TSH-secreting pituitary tumor is a mechanism for hormone resistance.
Alterations in the subcellular distribution of Guanylate cyclase and its responsiveness to nitric oxide in diethylstilbestrol-induced renal tumors.
An Analysis of the Multifaceted Roles of Heme in the Pathogenesis of Cancer and Related Diseases.
Antibody-drug conjugate directed against the guanylyl cyclase antigen for the treatment of gastrointestinal malignancies.
Applications of nanoparticles to diagnostics and therapeutics in colorectal cancer.
Bile Acids Induce Ectopic Expression of Intestinal Guanylyl Cyclase C Through Nuclear Factor-kappaB and Cdx2 in Human Esophageal Cells.
Bioactive compounds in plant materials for the prevention of diabetesand obesity.
Biochemical evidence of cocarcinogenesis: tumor promoting agent enhances methylnitrosourea activation of rat guanylate cyclase activity.
C-type natriuretic peptide and its precursor: potential markers in human prostate cancer.
Calcineurin Regulates Homologous Desensitization of Natriuretic Peptide Receptor-A and Inhibits ANP-Induced Testosterone Production in MA-10 Cells.
Carnosine as a regulator of soluble guanylate cyclase.
Cellular mechanisms by which tumor necrosis factor-alpha produces disruption of the blood-brain barrier.
Combined application of camptothecin and the guanylate cyclase activator YC-1: Impact on cell death and apoptosis-related proteins in ovarian carcinoma cell lines.
Corruption of homeostatic mechanisms in the guanylyl cyclase C signaling pathway underlying colorectal tumorigenesis.
Cyclic GMP and guanylate cyclase mediate lipopolysaccharide-induced Kupffer cell tumor necrosis factor-alpha synthesis.
Cyclic GMP-dependent protein kinase activation and induction by exisulind and CP461 in colon tumor cells.
Cyclic nucleotide metabolism in differentiated and undifferentiated epithelial thyroid cells in culture.
Cyclic nucleotide metabolism in solid tumor tissues.
Design, synthesis and investigation of the mechanism of action underlying anti-leukemic effects of the quinolinequinones as LY83583 analogs.
Does stage II colorectal cancer need to be redefined?
Ectopic expression of guanylyl cyclase C in CD34+ progenitor cells in peripheral blood.
Effect of lipoteichoic acid on dermal vascular permeability in mice.
Endothelial-Specific Notch Blockade Inhibits Vascular Function and Tumor Growth through an eNOS-Dependent Mechanism.
Epitope-targeted cytotoxic T cells mediate lineage-specific antitumor efficacy induced by the cancer mucosa antigen GUCY2C.
Escherichia coli heat-stable toxin receptors in human colonic tumors.
Expression of the intestinal biomarkers Guanylyl cyclase C and CDX2 in poorly differentiated colorectal carcinomas.
Functional multiplicity of atrial natriuretic peptide receptors on cultured rat Leydig tumor cells.
Guanylate cyclase C as a target for prevention, detection, and therapy in colorectal cancer.
Guanylyl cyclase C as a biomarker for immunotherapies for the treatment of gastrointestinal malignancies.
Guanylyl cyclase C as a biomarker for targeted imaging and therapy of metastatic colorectal cancer.
Guanylyl cyclase C is a marker of intestinal metaplasia, dysplasia, and adenocarcinoma of the gastrointestinal tract.
Guanylyl cyclase C is a specific marker for differentiating primary and metastatic ovarian mucinous neoplasms.
Guanylyl cyclase C messenger RNA is a biomarker for recurrent stage II colorectal cancer.
Guanylyl cyclase C prevents colon cancer metastasis by regulating tumor epithelial cell matrix metalloproteinase-9.
Guanylyl cyclase C-induced immunotherapeutic responses opposing tumor metastases without autoimmunity.
Guanylyl cyclase C: a molecular marker for staging and postoperative surveillance of patients with colorectal cancer.
GUCY2C ligand replacement to prevent colorectal cancer.
Heme oxygenase-1 inhibits TNF-alpha-induced apoptosis in cultured fibroblasts.
Hydrogen peroxide alters splicing of soluble guanylyl cyclase and selectively modulates expression of splicing regulators in human cancer cells.
Immunocapture-LC/MS-Based Target Engagement Measurement in Tumor Plasma Membrane.
Impact of circulating free tumor cells in the peripheral blood of colorectal cancer patients during laparoscopic surgery.
Impact of NPR-A expression in gastric cancer cells.
In vivo imaging of human colon cancer xenografts in immunodeficient mice using a guanylyl cyclase C--specific ligand.
In vivo xenoestrogenic actions of cadmium and arsenic in anterior pituitary and uterus.
Increased circulating concentration of the N-terminus of the atrial natriuretic factor prohormone in persons with pheochromocytomas.
Increased guanylate cyclase activity and guanosine 3',5'-monophosphate content in ethionine-induced hepatomas.
Inhibition of angiogenesis in human glioma cell lines by antisense RNA from the soluble guanylate cyclase genes, GUCY1A3 and GUCY1B3.
Inhibition of growth and guanylate cyclase activity of an undifferentiated prostate adenocarcinoma by an extract of the balsam pear (Momordica charantia abbreviata).
Inhibition of nitroso chemical carcinogen activation of rat hepatic guanylate cyclase by anticancer agents.
Inhibition of proinflammatory tumor necrosis factor-{alpha}-induced inducible nitric-oxide synthase by xanthine-based 7-[2-[4-(2-chlorobenzene)piperazinyl]ethyl]-1,3-dimethylxanthine (KMUP-1) and 7-[2-[4-(4-nitrobenzene)piperazinyl]ethyl]-1, 3-dimethylxanthine (KMUP-3) in rat trachea: The involvement of soluble guanylate cyclase and protein kinase G.
Intestinal GUCY2C Prevents TGF-? Secretion Coordinating Desmoplasia and Hyperproliferation in Colorectal Cancer.
Intravasation-related metastatic factors in colorectal cancer.
Investigations for a multi-marker RT-PCR to improve sensitivity of disseminated tumor cell detection.
Lack of guanylyl cyclase C, the receptor for Escherichia coli heat-stable enterotoxin, results in reduced polyp formation and increased apoptosis in the multiple intestinal neoplasia (Min) mouse model.
Mediation by nitric oxide formation in the preoptic area of endotoxin and tumour necrosis factor-induced inhibition of water intake in the rat.
Molecular signature detection of circulating tumor cells using a panel of selected genes.
Mucosally restricted antigens as novel immunological targets for antitumor therapy.
Natriuretic peptide receptor A as a novel target for cancer.
Natriuretic peptide receptors of type A in human neuroblastomas.
Nitric oxide enhances PGI(2)production by human pulmonary artery smooth muscle cells.
Nitric oxide suppresses the expression of Bcl-2 binding protein BNIP3 in hepatocytes.
Nitric oxide-mediated promotion of mammary tumour cell migration requires sequential activation of nitric oxide synthase, guanylate cyclase and mitogen-activated protein kinase.
NPR-A: A Therapeutic Target in Inflammation and Cancer.
Participation of the NO/cGMP/K+ATP pathway in the antinociception induced by Walker tumor bearing in rats.
Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced glioma cells.
PGE2 and PGA2 affect the allosteric properties and the activities of calmodulin-dependent guanylate cyclase and Ca2+-stimulated ATPase of Walker-256 tumour microsomal membranes.
Pharmacokinetics and Catabolism of [3H]TAK-164, a Guanylyl Cyclase C Targeted Antibody-Drug Conjugate.
Phenotypic characterization, karyotype analysis and in vitro tamoxifen sensitivity of new ER-negative vulvar carcinoma cell lines, UM-SCV-1A and UM-SCV-1B.
Potentiation of tumor necrosis factor-alpha expression by YC-1 in alveolar macrophages through a cyclic GMP-independent pathway.
Previstage GCC Colorectal Cancer Staging Test: A New Molecular Test to Identify Lymph Node Metastases and Provide More Accurate Information about the Stage of Patients with Colorectal Cancer.
Proliferative signaling by store-operated calcium channels opposes colon cancer cell cytostasis induced by bacterial enterotoxins.
Properties of guanylate cyclase from rat kidney cortex and transplantable kidney tumors.
Protection against TNF-induced lethal shock by soluble guanylate cyclase inhibition requires functional inducible nitric oxide synthase.
PTHrP and the PTH/PTHrP receptor are co-expressed in human breast and colon tumours.
Radiometallated peptides targeting guanylate cyclase C and the urokinase-type plasminogen activator receptor.
Sex modulates intestinal transformation by the tumor-suppressor GCC.
Small bowel carcinoid (enterochromaffin cell) neoplasia exhibits transforming growth factor-beta1-mediated regulatory abnormalities including up-regulation of C-Myc and MTA1.
Soluble Guanylate Cyclase Inhibitors Discovered among Natural Compounds.
Soluble guanylyl cyclase ?1 and p53 cytoplasmic sequestration and down-regulation in prostate cancer.
Sphingomyelin nanosystems loaded with uroguanylin and etoposide for treating metastatic colorectal cancer.
Studies on cyclic nucleotides in cancer. I. Adenylate guanylate cyclase and protein kinases in the prostatic sarcoma tissue.
The First "Zero-Length" Mass Spectrometry-Cleavable Cross-Linker for Protein Structure Analysis.
The Guanylate Cyclase C-cGMP Signaling Axis Opposes Intestinal Epithelial Injury and Neoplasia.
The paracrine hormone hypothesis of colorectal cancer.
The putative tumor suppressor Cdx2 is overexpressed by human colorectal adenocarcinomas.
The sGC-cGMP Signaling Pathway as a Potential Therapeutic Target in Doxorubicin-Induced Heart Failure: A Narrative Review.
Transforming growth factor beta 2 inhibits interleukin 1 beta- and tumour necrosis factor alpha-induction of nitric oxide synthase in rat renal mesangial cells.
Translating colorectal cancer prevention through the guanylyl cyclase C signaling axis.
Tumor necrosis factor alpha activates soluble guanylate cyclase in bovine glomerular mesangial cells via an L-arginine-dependent mechanism.
What is next in nitric oxide research? From cardiovascular system to cancer biology.
[Concentration of cyclic nucleotides, activity of adenylate cyclase, 3',5'-AMP phosphodiesterase and guanylate cyclase in plasma membranes from liver and hepatomas of different degrees of malignancy]
[Guanyl cyclase and cyclic guanosine 3',5'-monosphate-phosphodiesterase in human cerebral tumors]
Neoplastic Cells, Circulating
Ectopic expression of guanylyl cyclase C in CD34+ progenitor cells in peripheral blood.
Neuralgia
cGMP produced by NO-sensitive guanylyl cyclase essentially contributes to inflammatory and neuropathic pain by using targets different from cGMP-dependent protein kinase I.
Distinct functions of soluble guanylyl cyclase isoforms NO-GC1 and NO-GC2 in inflammatory and neuropathic pain processing.
Nitric oxide mediates the thermal hyperalgesia produced in a model of neuropathic pain in the rat.
Post-Transcriptional Regulation of Soluble Guanylate Cyclase that Governs Neuropathic Pain in Alzheimer's Disease.
The nitric oxide-cyclic GMP pathway is required for nociceptive signalling at specific loci within the somatosensory pathway.
The regulation of sGC on the rat model of neuropathic pain is mediated by 5-HT1ARs and NO/cGMP pathway.
Neurilemmoma
Regulation of the cyclic guanosine 3'-5' monophosphate system in human brain tumors.
Neuroblastoma
1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one inhibits neurite outgrowth and causes neurite retraction in PC12 cells independently of soluble guanylyl cyclase.
Activation by nitric oxide of guanylate cyclase in endothelial cells from brain capillaries.
Activation of neuronal nitric oxide synthase by M2 muscarinic receptors associated with a small increase in intracellular calcium.
Acute effects of ethanol and other short-chain alcohols on the guanylate cyclase system of murine neuroblastoma cells (clone N1E-115).
Biological studies of a nitroso compound that releases nitric oxide upon illumination.
CCAAT-binding factor regulates expression of the beta1 subunit of soluble guanylyl cyclase gene in the BE2 human neuroblastoma cell line.
Development of guanine analyzer to measure activity of guanylate cyclase.
Differential coupling of m1, m3, and m5 muscarinic receptors to activation of neuronal nitric oxide synthase.
Effects of arginine derivatives on soluble guanylate cyclase from neuroblastoma N1E 115 cells.
Guanylate cyclase in neuroblastoma N1E 115 cells: presence of endogenous activator.
Human A-type ANP receptor upregulation by PACAP and carbachol in neuroblastoma cells.
Inhibition by lithium of cyclic GMP formation without inhibition of nitric oxide generation in the mouse neuroblastoma cell (N1E-115).
L-Arginine identified as an endogenous activator for soluble guanylate cyclase from neuroblastoma cells.
Methylene blue induces cytotoxicity in human brain tumor cells.
N-hydroxylamine is not an intermediate in the conversion of L-arginine to an activator of soluble guanylate cyclase in neuroblastoma N1E-115 cells.
Natriuretic peptide receptors of type A in human neuroblastomas.
New signaling mechanism of angiotensin II in neuroblastoma neuro-2A cells: activation of soluble guanylyl cyclase via nitric oxide synthesis.
Occupancy of muscarinic acetylcholine receptors stimulates a guanylate cyclase in neuroblastoma cells.
Production and properties of antibody to soluble guanylate cyclase purified from bovine brain.
Proliferative actions of natriuretic peptides on neuroblastoma cells. Involvement of guanylyl cyclase and non-guanylyl cyclase pathways.
Receptor-mediated generation of an EDRF-like intermediate in a neuronal cell line detected by spin trapping techniques.
Role of intracellular Ca2+ mobilization in muscarinic and histamine receptor-mediated activation of guanylate cyclase in N1E-115 neuroblastoma cells: assessment of the arachidonic acid release hypothesis.
Selective activation of particulate guanylate cyclase by a specific class of porphyrins.
The effect of unsaturated fatty acids on sodium nitroprusside stimulation of guanylate cyclase in the human astrocytoma clone, D384, and the human neuroblastoma clone, NB1-G.
Neurodegenerative Diseases
Effects of the JNK inhibitor anthra[1,9-cd]pyrazol-6(2H)-one (SP-600125) on soluble guanylyl cyclase alpha1 gene regulation and cGMP synthesis.
Molecular docking analysis of phytoconstituent from Momordica charantia with Guanylate Cyclase catalytic domain.
Nitric oxide-cyclic GMP signaling pathway limits inflammatory degeneration of midbrain dopaminergic neurons: cell type-specific regulation of heme oxygenase-1 expression.
NO chimeras as therapeutic agents in Alzheimer's disease.
The CNS-Penetrant Soluble Guanylate Cyclase Stimulator CY6463 Reveals its Therapeutic Potential in Neurodegenerative Diseases.
Neuromuscular Diseases
Guanylate cyclase activity in normal and diseased human muscle.
Night Blindness
GUCY2D mutations in retinal guanylyl cyclase 1 provide biochemical reasons for dominant cone-rod dystrophy but not for stationary night blindness.
Obesity
Defective development and microcirculation of intestine in Npr2 mutant mice.
Effect of hereditary obesity on renal expressions of NO synthase, caveolin-1, AKt, guanylate cyclase, and calmodulin.
From bedside to bench--meeting report of the 7th International Conference on cGMP "cGMP: generators, effectors and therapeutic implications" in Trier, Germany, from June 19th to 21st 2015.
Guanylyl Cyclase C Hormone Axis at the Intersection of Obesity and Colorectal Cancer.
High-fat diet-induced obesity leads to increased NO sensitivity of rat coronary arterioles: role of soluble guanylate cyclase activation.
Liraglutide suppresses obesity and induces brown fat-like phenotype via Soluble Guanylyl Cyclase mediated pathway in vivo and in vitro.
Natriuretic peptides promote glucose uptake in a cGMP-dependent manner in human adipocytes.
Omentin changes following bariatric surgery and predictive links with biomarkers for risk of cardiovascular disease.
Pilot Study Measuring the Novel Satiety Hormone, Pro-Uroguanylin, in Adolescents With and Without Obesity.
Platelet resistance to the antiaggregating effect of N-acetyl-L-cysteine in obese, insulin-resistant subjects.
Reduced NO-cGMP signaling contributes to vascular inflammation and insulin resistance induced by high-fat feeding.
Stimulation of soluble guanylyl cyclase protects against obesity by recruiting brown adipose tissue.
The Importance of Natriuretic Peptides in Cardiometabolic Diseases.
Ocular Hypertension
A Randomized, Controlled Phase I/II Study to Evaluate the Safety and Efficacy of MGV354 for Ocular Hypertension or Glaucoma.
Oliguria
Guanylyl Cyclase A in Both Renal Proximal Tubular and Vascular Endothelial Cells Protects the Kidney against Acute Injury in Rodent Experimental Endotoxemia Models.
Opioid-Induced Constipation
Update on the management of constipation in the elderly: new treatment options.
Optic Nerve Diseases
Soluble Guanylate Cyclase ?1-Deficient Mice: A Novel Murine Model for Primary Open Angle Glaucoma.
Osteoarthritis
cGMP levels in chronic cadmium disease and osteoarthritis.
Osteochondrodysplasias
C-type natriuretic peptide regulation of limb mesenchymal chondrogenesis is accompanied by altered N-cadherin and collagen type X-related functions.
Osteoporosis
From bedside to bench--meeting report of the 7th International Conference on cGMP "cGMP: generators, effectors and therapeutic implications" in Trier, Germany, from June 19th to 21st 2015.
Soluble guanylate cyclase as a novel treatment target for osteoporosis.
Osteoporosis, Postmenopausal
Soluble guanylate cyclase as a novel treatment target for osteoporosis.
Ovarian Neoplasms
Impact of NPR-A expression in gastric cancer cells.
Natriuretic peptide receptor A as a novel target for cancer.
Notch activation augments nitric oxide/soluble guanylyl cyclase signaling in immortalized ovarian surface epithelial cells and ovarian cancer cells.
Regulation of p53 and suppression of apoptosis by the soluble guanylyl cyclase/cGMP pathway in human ovarian cancer cells.
Pancreatic Neoplasms
A monomethyl auristatin E-conjugated antibody to guanylyl cyclase C is cytotoxic to target-expressing cells in vitro and in vivo.
Evaluation of TAK-264, an Antibody-Drug Conjugate in Pancreatic Cancer Cell Lines and Patient-Derived Xenograft Models.
Guanylyl cyclase C as a biomarker for immunotherapies for the treatment of gastrointestinal malignancies.
Pancreatitis
Guanylate cyclase inhibition by methylene blue in circulatory shock caused by acute necrotizing pancreatitis: a word of caution based on a porcine model.
[Changes of guanylate cyclase C in colon tissues of rats with intestinal injury associated with severe acute pancreatitis].
Pancreatitis, Acute Necrotizing
Guanylate cyclase inhibition by methylene blue in circulatory shock caused by acute necrotizing pancreatitis: a word of caution based on a porcine model.
Papilloma
Guanylate cyclase activity in normal and neoplastic squamous epithelia from the upper aero-digestive tract.
Immortalization of human melanocytes does not alter the de novo properties of nitric oxide to induce cell detachment from extracellular matrix components via cGMP.
Parkinson Disease
Nitric oxide-cyclic GMP signaling pathway limits inflammatory degeneration of midbrain dopaminergic neurons: cell type-specific regulation of heme oxygenase-1 expression.
Retrospection on the Role of Soluble Guanylate Cyclase in Parkinson's Disease.
Role of nitric oxide in the regulation of motor function. An overview of behavioral, biochemical and histological studies in animal models.
Parkinsonian Disorders
Alterations of the expression and activity of midbrain nitric oxide synthase and soluble guanylyl cyclase in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice.
Periodontitis
[Adenylate cyclase and guanylate cyclase in the saliva of healthy persons and in periodontitis]
Peritoneal Fibrosis
Deficiency of endothelial nitric oxide signaling pathway exacerbates peritoneal fibrosis in mice.
Pheochromocytoma
Activation of soluble guanylate cyclase through phosphorylation by protein kinase C in intact PC12 cells.
Increased circulating concentration of atrial natriuretic factor in persons with pheochromocytomas.
Increased circulating concentration of the N-terminus of the atrial natriuretic factor prohormone in persons with pheochromocytomas.
Nerve growth factor decreases soluble guanylate cyclase in rat pheochromocytoma PC12 cells.
Neuromodulatory effects of atrial natriuretic factor are independent of guanylate cyclase in adrenergic neuronal pheochromocytoma cells.
Neuromodulatory effects of atrial natriuretic peptides correlate with an inhibition of adenylate cyclase but not an activation of guanylate cyclase.
Stimulation of the cyclic GMP pathway by NO induces expression of the immediate early genes c-fos and junB in PC12 cells.
[Studies on the cytological function of the biomembrane and the neurons]
Photophobia
Mg2+/Ca2+ cation binding cycle of guanylyl cyclase activating proteins (GCAPs): role in regulation of photoreceptor guanylyl cyclase.
Occupancy of the chromophore binding site of opsin activates visual transduction in rod photoreceptors.
Plasmacytoma
Manganese and magnesium dependent properties and inner plasma membrane surface localization of guanylate cyclase from murine plasmocytoma cells.
Porcine Reproductive and Respiratory Syndrome
DNA Sensing across the Tree of Life.
Porphyrias
Interactions of acetamide and acrylamide with heme models: Synthesis, infrared spectra, and solid state molecular structures of five- and six-coordinate ferric porphyrin derivatives.
Pre-Eclampsia
Aberrant pro-atrial natriuretic peptide/corin/natriuretic peptide receptor signaling is present in maternal vascular endothelium in preeclampsia.
Atrial natriuretic peptide and sodium azide dependent guanylate cyclase activities in placentas from normal and severely toxemic patients.
Different effects of different phosphodiesterase type-5 inhibitors in pre-eclampsia.
Endothelial Dysfunction in the Human Umbilical Artery due to Preeclampsia Can Be Prevented by Sildenafil.
Investigation of the role of the NO-cGMP pathway on YC-1 and DEA/NO effects on thoracic aorta smooth muscle responses in a rat preeclampsia model.
Is Atrial Natriuretic Peptide (ANP) and Natriuretic Peptide Receptor-A (NPR-A) Expression in Human Placenta and Decidua Normal?
Plasma cyclic GMP concentrations and their relationship with changes of blood pressure levels in pre-eclampsia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Adenylate cyclase and guanylate cyclase activity in normal and leukemic human lymphocytes.
Premature Ejaculation
Vas deferens smooth muscle responses to the nitric oxide-independent soluble guanylate cyclase stimulator BAY 41-2272.
Pressure Ulcer
A hopeful prospect of riociguat as a soluble guanylate cyclase stimulator for management of pressure ulcers.
Priapism
Alternative approaches to the management of priapism.
Primary Dysautonomias
Cyclic nucleotide regulation of cardiac sympatho-vagal responsiveness.
Prostatic Hyperplasia
The Endothelium-Dependent Nitric Oxide-cGMP Pathway.
Prostatic Neoplasms
A peptide against soluble guanylyl cyclase ?1: a new approach to treating prostate cancer.
Androgen regulation of soluble guanylyl cyclasealpha1 mediates prostate cancer cell proliferation.
cGMP-independent anti-tumour actions of the inhibitor of soluble guanylyl cyclase, ODQ, in prostate cancer cell lines.
COP9 Subunits 4 and 5 Target Soluble Guanylyl Cyclase ?1 and p53 in Prostate Cancer Cells.
Gene Expression Profiling Analysis Reveals Putative Phytochemotherapeutic Target for Castration-Resistant Prostate Cancer.
Inhibition of nitroso chemical carcinogen activation of rat hepatic guanylate cyclase by anticancer agents.
Peptide B targets soluble guanylyl cyclase ?1 and kills prostate cancer cells.
Soluble guanylyl cyclase ?1 and p53 cytoplasmic sequestration and down-regulation in prostate cancer.
The bradykinin/soluble guanylate cyclase signaling pathway is impaired in androgen-independent prostate cancer cells.
Prostatitis
Expression and Regulation of Brain Natriuretic Peptide and Natriuretic Peptide Receptor A (NPR-A) in L6-S1 Dorsal Root Ganglia in a Rat Model of Chronic Nonbacterial Prostatitis.
[Expressions of BNP and NPR-A in rat models of chronic nonbacterial prostatitis and their significance].
Proteinuria
Stimulation of soluble guanylate cyclase slows progression in anti-thy1-induced chronic glomerulosclerosis.
Psoriasis
Cyclic GMP metabolism in psoriasis: activation of soluble epidermal guanylate cyclase by arachidonic acid and 12-hydroxy-5,8,10,14-eicosatetraenoic acid.
Pulmonary Arterial Hypertension
A Bayesian network meta-analysis on the efficacy and safety of eighteen targeted drugs or drug combinations for pulmonary arterial hypertension.
Acute effects of riociguat in borderline or manifest pulmonary hypertension associated with chronic obstructive pulmonary disease.
Change of right heart size and function by long-term therapy with riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Comparative Safety of Drugs Targeting the Nitric Oxide Pathway in Pulmonary Hypertension: A Mixed Approach Combining a Meta-analysis of Clinical Trials and a Disproportionality Analysis From the World Health Organization Pharmacovigilance Database.
Comparison of the crystal structures and thermochemistry of a novel soluble guanylate cyclase stimulator riociguat and its solvates.
Effects of age and sex on the pharmacokinetics of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521).
Effects of Sevoflurane on Hemodynamics and Inducible Nitric Oxide Synthase/Soluble Guanylate Cyclase Signaling Pathway in a Rat Model of Pulmonary Arterial Hypertension.
Efficacy and safety of riociguat in combination therapy for patients with pulmonary arterial hypertension (PATENT studies).
Efficacy and safety of riociguat in the treatment of chronic thromboembolic pulmonary arterial hypertension: A meta-analysis.
Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension.
First-in-child use of the oral soluble guanylate cyclase stimulator riociguat in pulmonary arterial hypertension.
Improving Survival in Patients with Pulmonary Arterial Hypertension: Focus on Intravenous Epoprostenol.
In vitro-in vivo correlation of the drug-drug interaction potential of antiretroviral HIV treatment regimens on CYP1A1 substrate riociguat.
In vitroand in vivo investigation of metabolic fate of riociguat by HPLC-Q-TOF/MS/MS and in silico evaluation of the metabolites by ADMET predictor™.
Individual dose adjustment of riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
NO-sensitive guanylyl cyclase in the lung.
Pharmacokinetic interaction of riociguat and antiretroviral combination regimens in HIV-1-infected adults.
Pharmacokinetic interaction profile of riociguat, a new soluble guanylate cyclase stimulator, in vitro.
Phosphodiesterase type 5 inhibitor to riociguat transition is associated with hemodynamic and symptomatic improvement in pulmonary hypertension.
Pulmonary Hypertension in Adults with Congenital Heart Disease: Real-World Data from the International COMPERA-CHD Registry.
Reversal of severe angioproliferative pulmonary arterial hypertension and right ventricular hypertrophy by combined phosphodiesterase-5 and endothelin receptor inhibition.
Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study).
Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study.
Riociguat for the treatment of pulmonary arterial hypertension.
Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2).
Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry.
Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry.
Riociguat, a soluble guanylate cyclase stimulator, ameliorates right ventricular contraction in pulmonary arterial hypertension.
Riociguat: a novel new drug for treatment of pulmonary hypertension.
Riociguat: a review of its use in patients with chronic thromboembolic pulmonary hypertension or pulmonary arterial hypertension.
Riociguat: Clinical research and evolving role in therapy.
Riociguat: first global approval.
Soluble guanylate cyclase stimulator, trans-4-methoxy-?-nitrostyrene, has a beneficial effect in monocrotaline-induced pulmonary arterial hypertension in rats.
Soluble guanylate cyclase: a new therapeutic target for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Switching from sildenafil to riociguat for the treatment of PAH and inoperable CTEPH: Real-life experiences.
Systemic Sclerosis and Systemic Lupus Erythematosus Overlap Syndrome with Pulmonary Arterial Hypertension Successfully Treated with Immunosuppressive Therapy and Riociguat.
Targeting soluble guanylate cyclase for the treatment of pulmonary hypertension.
The Soluble Guanylate Cyclase Stimulator Riociguat Ameliorates Pulmonary Hypertension Induced by Hypoxia and SU5416 in Rats.
The soluble guanylate cyclase stimulator, 1-nitro-2-phenylethane, reverses monocrotaline-induced pulmonary arterial hypertension in rats.
Treatment Selection in Pulmonary Arterial Hypertension: Phosphodiesterase Type 5 Inhibitors versus Soluble Guanylate Cyclase Stimulator.
YC-1 attenuates hypoxia-induced pulmonary arterial hypertension in mice.
[Cellular signalling pathways and pathophysiology of pulmonary arterial hypertension.]
[Diagnosis and treatment of pulmonary hypertension].
[The achievements of the modern specific therapy of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: focus on the stimulator of soluble guanylate cyclase riociguat].
Pulmonary Disease, Chronic Obstructive
Guanylyl Cyclase Activation Reverses Resistive Breathing-induced Lung Injury and Inflammation.
Inhaled sGC Modulator Can Lower PH in Patients With COPD Without Deteriorating Oxygenation.
Soluble guanylate cyclase stimulation reduces oxidative stress in experimental Chronic Obstructive Pulmonary Disease.
The Role of Soluble Guanylyl Cyclase in Chronic Obstructive Pulmonary Disease.
Pulmonary Edema
Atrial natriuretic peptide attenuates agonist-induced pulmonary edema in mice with targeted disruption of the gene for natriuretic peptide receptor-A.
Pulmonary Embolism
A soluble guanylate cyclase stimulator, BAY 41-8543, preserves right ventricular function in experimental pulmonary embolism.
Dose-dependent beneficial hemodynamic effects of BAY 41-2272 in a canine model of acute pulmonary thromboembolism.
Pulmonary vascular reserve during experimental pulmonary embolism: Effects of a soluble guanylate cyclase stimulator, BAY 41-8543.
Riociguat, sildenafil and inhaled nitric oxide reduces pulmonary vascular resistance and improves right ventricular function in a porcine model of acute pulmonary embolism.
Pulmonary Fibrosis
NO-sensitive guanylyl cyclase in the lung.
Rectal Neoplasms
Expression of guanylyl cyclase C in tissue samples and the circulation of rectal cancer patients.
Renal Insufficiency
From bedside to bench--meeting report of the 7th International Conference on cGMP "cGMP: generators, effectors and therapeutic implications" in Trier, Germany, from June 19th to 21st 2015.
The guanylate cyclase C agonist linaclotide ameliorates the gut-cardio-renal axis in an adenine-induced mouse model of chronic kidney disease.
Renal Insufficiency, Chronic
NO-independent activation of soluble guanylate cyclase prevents disease progression in rats with 5/6 nephrectomy.
Renal effects of soluble guanylate cyclase stimulators and activators: A review of the preclinical evidence.
Stimulation of soluble guanylate cyclase slows progression in anti-thy1-induced chronic glomerulosclerosis.
The guanylate cyclase C agonist linaclotide ameliorates the gut-cardio-renal axis in an adenine-induced mouse model of chronic kidney disease.
Reperfusion Injury
Analysis of vasodilator responses to peroxynitrite in the hindlimb vascular bed of the cat.
Nitroglycerin reperfusion reduces ischemia-reperfusion injury in non-heart-beating donor lungs.
Protection through postconditioning or a mitochondria-targeted S-nitrosothiol is unaffected by cardiomyocyte-selective ablation of protein kinase G.
Protein kinase A dependent signalling mediates anti-apoptotic effects of the atrial natriuretic peptide in ischemic livers.
Soluble guanylate cyclase-{alpha}1 is required for the cardioprotective effects of inhaled nitric oxide.
The Carbon monoxide releasing molecule ALF-186 mediates anti-inflammatory and neuroprotective effects via the soluble guanylate cyclase ß1 in rats' retinal ganglion cells after ischemia and reperfusion injury.
Toll-like receptor 4 signaling confers cardiac protection against ischemic injury via inducible nitric oxide synthase- and soluble guanylate cyclase-dependent mechanisms.
Urodilatin limits acute reperfusion injury in the isolated rat heart.
Respiratory Distress Syndrome
NO-sensitive guanylyl cyclase in the lung.
Retinal Degeneration
A null mutation in the photoreceptor guanylate cyclase gene causes the retinal degeneration chicken phenotype.
Accumulation of calcium in degenerating photoreceptors of several Drosophila mutants.
Chemical shift assignments of retinal degeneration 3 protein (RD3).
Constitutive excitation by Gly90Asp rhodopsin rescues rods from degeneration caused by elevated production of cGMP in the dark.
Dimerization Domain of Retinal Membrane Guanylyl Cyclase 1 (RetGC1) Is an Essential Part of Guanylyl Cyclase-activating Protein (GCAP) Binding Interface.
Dominant Cone-Rod Dystrophy: A Mouse Model Generated by Gene Targeting of the GCAP1/Guca1a Gene.
Dysfunction of outer segment guanylate cyclase caused by retinal disease related mutations.
Functional Study and Mapping Sites for Interaction with the Target Enzyme in Retinal Degeneration 3 (RD3) Protein.
Genetic expression of cyclic GMP phosphodiesterase activity defines abnormal photoreceptor differentiation in neurological mutants of inherited retinal degeneration.
Increased light exposure alleviates one form of photoreceptor degeneration marked by elevated calcium in the dark.
Methylene Blue Prevents Retinal Damage Caused by Perinatal Asphyxia in the Rat.
Novel GUCA1A mutation identified in a Chinese family with cone-rod dystrophy.
Novel GUCA1A Mutations Suggesting Possible Mechanisms of Pathogenesis in Cone, Cone-Rod, and Macular Dystrophy Patients.
Phosphoinositide Metabolism in Drosophila Phototransduction: A Coffee Break Discussion Leads to 30 Years of History.
Retinal degeneration 3 (RD3) protein inhibits catalytic activity of retinal membrane guanylyl cyclase (RetGC) and its stimulation by activating proteins.
Retinal degeneration 3 (RD3) protein, a retinal guanylyl cyclase regulator, forms a monomeric and elongated four-helix bundle.
Retinal Degeneration Protein 3 (RD3) in normal human tissues: Novel insights.
Retinal degeneration-3 protein attenuates photoreceptor degeneration in transgenic mice expressing dominant mutation of human retinal guanylyl cyclase.
Retinal Diseases
Bicarbonate Modulates Photoreceptor Guanylate Cyclase (ROS-GC) Catalytic Activity.
Dysfunction of outer segment guanylate cyclase caused by retinal disease related mutations.
Enzymatic relay mechanism stimulates cyclic GMP synthesis in rod photoresponse: biochemical and physiological study in guanylyl cyclase activating protein 1 knockout mice.
Factors that affect regulation of cGMP synthesis in vertebrate photoreceptors and their genetic link to human retinal degeneration.
First 3D-Structural Data of Full-Length Guanylyl Cyclase 1 in Rod-Outer-Segment Preparations of Bovine Retina by Cross-Linking/Mass Spectrometry.
Human retinal guanylate cyclase (GUC2D) maps to chromosome 17p13.1.
Identification of Target Binding Site in Photoreceptor Guanylyl Cyclase-activating Protein 1 (GCAP1).
Involvement of rhodopsin and ATP in the activation of membranous guanylate cyclase in retinal photoreceptor outer segments (ROS-GC) by GC-activating proteins (GCAPs): a new model for ROS-GC activation and its link to retinal diseases.
Localisation of a gene for central areolar choroidal dystrophy to chromosome 17p.
Regulation of cGMP synthesis in photoreceptors: role in signal transduction and congenital diseases of the retina.
Retinal diseases linked with photoreceptor guanylate cyclase.
Retinal Dystrophies
A decrease in guanylate cyclase activity in some tissues of C3H/HeJ mice with retinal dystrophy.
Activation of retinal guanylyl cyclase RetGC1 by GCAP1: stoichiometry of binding and effect of new LCA-related mutations.
Functional analyses of mutant recessive GUCY2D alleles identified in Leber congenital amaurosis patients: protein domain comparisons and dominant negative effects.
Genetic analysis of the guanylate cyclase activator 1B (GUCA1B) gene in patients with autosomal dominant retinal dystrophies.
Impaired Association of Retinal Degeneration-3 with Guanylate Cyclase-1 and Guanylate Cyclase-activating Protein-1 Leads to Leber Congenital Amaurosis-1.
Insights gained from gene therapy in animal models of retGC1 deficiency.
Membrane guanylate cyclase, a multimodal transduction machine: history, present, and future directions.
Organization of the canine gene encoding the E isoform of retinal guanylate cyclase (cGC-E) and exclusion of its involvement in the inherited retinal dystrophy of the Swedish Briard and Briard-beagle dogs.
Photoreceptor Guanylate Cyclase (GUCY2D) Mutations Cause Retinal Dystrophies by Severe Malfunction of Ca2+-Dependent Cyclic GMP Synthesis.
Reanalysis of Association of Pro50Leu Substitution in Guanylate Cyclase Activating Protein-1 With Dominant Retinal Dystrophy.
Retinitis Pigmentosa
Cone dystrophy or macular dystrophy associated with novel autosomal dominant GUCA1A mutations.
Mutations that are a common cause of Leber congenital amaurosis in northern America are rare in Southern India.
Novel GUCA1A mutation identified in a Chinese family with cone-rod dystrophy.
shRNA knockdown of guanylate cyclase 2e or cyclic nucleotide gated channel alpha 1 increases photoreceptor survival in a cGMP phosphodiesterase mouse model of retinitis pigmentosa.
Sarcoma
Guanylate cyclase and cyclic guanosine 3':5'-monophosphate phosphodiesterase activities and cyclic guanosine 3':5'-monophosphate levels in normal and transformed fibroblasts in culture.
Studies on cyclic nucleotides in cancer. I. Adenylate guanylate cyclase and protein kinases in the prostatic sarcoma tissue.
Scleroderma, Systemic
A multicenter randomized, double-blind, placebo-controlled pilot study to assess the efficacy and safety of riociguat in systemic sclerosis-associated digital ulcers.
Protein kinases G are essential downstream mediators of the antifibrotic effects of sGC stimulators.
Soluble guanylate cyclase stimulator reduced the gastrointestinal fibrosis in bleomycin-induced mouse model of systemic sclerosis.
Systemic Sclerosis and Systemic Lupus Erythematosus Overlap Syndrome with Pulmonary Arterial Hypertension Successfully Treated with Immunosuppressive Therapy and Riociguat.
The role of pulmonary arterial hypertension-targeted therapy in systemic sclerosis.
Seizures
Involvement of nNOS, and ?1, ?2, ?1, and ?2 Subunits of Soluble Guanylyl Cyclase Genes Expression in Anticonvulsant Effect of Sumatriptan on Pentylenetetrazole-Induced Seizure in Mice.
L-arginine potentiates excitatory amino acid-induced seizures elicited in the deep prepiriform cortex.
Nitric oxide: an endogenous anticonvulsant substance.
Protective effect of NG-nitro-L-arginine (N5-[imino(nitroamino)methyl]-L-ornithine) against cyanide-induced convulsions in mice.
Regulation of activity-dependent neuroprotective protein (ADNP) by the NO-cGMP pathway in the hippocampus during kainic acid-induced seizure.
Role of nitric oxide in anticonvulsant effects of benzodiazepines in mice.
Sodium nitroprusside-induced seizure and taurine release from rat hippocampus.
Sepsis
Blockade of the action of nitric oxide in human septic shock increases systemic vascular resistance and has detrimental effects on pulmonary function after a short infusion of methylene blue.
C-Type Natriuretic Peptide Induces Anti-contractile Effect Dependent on Nitric Oxide, Oxidative Stress, and NPR-B Activation in Sepsis.
Carnosine as a regulator of soluble guanylate cyclase.
Decreased aortic smooth muscle contraction in a rat model of multibacterial sepsis.
Heme oxygenase-dependent carbon monoxide production is a hepatic adaptive response to sepsis.
INHIBITION OF GUANYLYL CYCLASE RESTORES NEUTROPHIL MIGRATION AND MAINTAINS BACTERICIDAL ACTIVITY INCREASING SURVIVAL IN SEPSIS.
Ionic imbalance and lack of effect of adjuvant treatment with methylene blue in the hamster model of leptospirosis.
Late, but not early, inhibition of soluble guanylate cyclase decreases mortality in a rat sepsis model.
Neuronal Nitric Oxide Synthase and Its Interaction With Soluble Guanylate Cyclase Is a Key Factor for the Vascular Dysfunction of Experimental Sepsis.
Nitric oxide and cardiovascular dysfunction in sepsis.
Nitric oxide and vascular reactivity in sepsis.
Protection against TNF-induced lethal shock by soluble guanylate cyclase inhibition requires functional inducible nitric oxide synthase.
Role of central NO-cGMP pathway in vasopressin and oxytocin gene expression during sepsis.
Role of Methylene Blue in the Maintenance of Postinduction Hemodynamic Status in Patients with Perforation Peritonitis: A Pilot Study.
sGC(alpha)1(beta)1 attenuates cardiac dysfunction and mortality in murine inflammatory shock models.
The Story of Nitric Oxide, Sepsis and Methylene Blue: A Comprehensive Pathophysiologic Review.
Shock, Septic
Blockade of the action of nitric oxide in human septic shock increases systemic vascular resistance and has detrimental effects on pulmonary function after a short infusion of methylene blue.
Carnosine as a regulator of soluble guanylate cyclase.
Differential effects of a selective inhibitor of soluble guanylyl cyclase on global and regional hemodynamics during canine endotoxic shock.
Does methylene blue administration to septic shock patients affect vascular permeability and blood volume?
Effect of methylene blue on middle cerebral artery flow velocity in a patient with severe sepsis following clipping of a cerebral aneurysm.
Effect of methylene blue on refractory neonatal hypotension.
Inhalative and intravenous stimulation of soluble guanylate cyclase reduces pulmonary vascular resistance and increases cardiac output in experimental septic shock.
Methylene blue administration in septic shock: a clinical trial.
Methylene blue increases systemic vascular resistance in human septic shock. Preliminary observations.
Methylene blue reverses endotoxin-induced hypotension.
Nitric oxide-independent activation of soluble guanylyl cyclase contributes to endotoxin shock in rats.
Role of nitric oxide and cGMP in human septic serum-induced depression of cardiac myocyte contractility.
The effects of methylene blue on hemodynamic parameters and cytokine levels in refractory septic shock.
[Does nitric oxide stress exist?]
Spasm
Nitric oxide donating aspirins: novel drugs for the treatment of saphenous vein graft failure.
Suppression of Graft Spasm by the Particulate Guanylyl Cyclase Activator in Coronary Bypass Surgery.
The mast cell.
Squamous Cell Carcinoma of Head and Neck
Soluble guanylate cyclase stimulators increase sensitivity to cisplatin in head and neck squamous cell carcinoma cells.
The cyclic GMP/protein kinase G pathway as a therapeutic target in head and neck squamous cell carcinoma.
Starvation
Guanylate cyclase activity in rat liver and other tissues with starvation and streptozotocin-induced diabetes mellitus.
Nitric oxide synthase is induced in sporulation of Physarum polycephalum.
Polyamines, NO and cGMP mediate stimulation of DNA synthesis by tumor necrosis factor and lipopolysaccharide in chick embryo cardiomyocytes.
Status Epilepticus
Influence of lesions of the noradrenergic locus coeruleus system on the cerebral metabolic response to bicuculline-induced seizures.
Stomach Diseases
The effect of class II major histocompatibility complex expression on adherence of Helicobacter pylori and induction of apoptosis in gastric epithelial cells: a mechanism for T helper cell type 1-mediated damage.
Stomach Neoplasms
Atrial natriuretic peptide modulates the proliferation of human gastric cancer cells via KCNQ1 expression.
Ectopic expression of guanylyl cyclase C and endogenous ligand guanylin correlates significantly with Helicobacter pylori infection in gastric carcinogenesis.
Ectopic expression of guanylyl cyclase C in gastric cancer as a potential biomarker and therapeutic target.
Impact of NPR-A expression in gastric cancer cells.
[Expression of guanylyl cyclase-c and caudal type homeobox transcription factor 2 in human gastric cancer and precursor lesions]
Stroke
Characterization of the human alpha1 beta1 soluble guanylyl cyclase promoter: key role for NF-kappaB(p50) and CCAAT-binding factors in regulating expression of the nitric oxide receptor.
Nitric oxide modulates cardiac performance in the heart of Anguilla anguilla.
Nitric oxide modulates the frog heart ventricle morphodynamics.
Soluble guanylate cyclase alpha1beta1 limits stroke size and attenuates neurological injury.
Soluble Guanylate Cyclase Stimulators: a Novel Treatment Option for Heart Failure Associated with Cardiorenal Syndromes?
Subarachnoid Hemorrhage
Alteration of basilar artery rho-kinase and soluble guanylyl cyclase protein expression in a rat model of cerebral vasospasm following subarachnoid hemorrhage.
Changes in endothelial nitric oxide synthase mRNA during vasospasm after subarachnoid hemorrhage in monkeys.
Nitric oxide synthase and guanylate cyclase levels in canine basilar artery after subarachnoid hemorrhage.
Reduced production of cGMP underlies the loss of endothelium-dependent relaxations in the canine basilar artery after subarachnoid hemorrhage.
Tachycardia
Contribution of iNOS/sGC/PKG pathway, COX-2, CYP4A1, and gp91(phox) to the protective effect of 5,14-HEDGE, a 20-HETE mimetic, against vasodilation, hypotension, tachycardia, and inflammation in a rat model of septic shock.
Hemin blunts the depressant effect of chronic nicotine on reflex tachycardia via activation of central NOS/PI3K pathway in female rats.
Nitric oxide in the insular cortex modulates baroreflex responses in a cGMP-independent pathway.
Tetanus
Mice deficient in endothelial nitric oxide synthase exhibit a selective deficit in hippocampal long-term potentiation.
On the respective roles of nitric oxide and carbon monoxide in long-term potentiation in the hippocampus.
Sequential activation of soluble guanylate cyclase, protein kinase G and cGMP-degrading phosphodiesterase is necessary for proper induction of long-term potentiation in CA1 of hippocampus. Alterations in hyperammonemia.
Synaptic transmission in neurons that express the Drosophila atypical soluble guanylyl cyclases, Gyc-89Da and Gyc-89Db, is necessary for the successful completion of larval and adult ecdysis.
Thrombocytopenia
Clinical comparison of QOL and adverse events during postoperative adjuvant chemotherapy in outpatients with node-positive colorectal cancer or gastric cancer.
Thromboembolism
In vitroand in vivo investigation of metabolic fate of riociguat by HPLC-Q-TOF/MS/MS and in silico evaluation of the metabolites by ADMET predictor™.
Thrombosis
Cardiovascular consequences when nitric oxide and lipid signaling converge.
Comparative Studies of the Dynamics Effects of BAY60-2770 and BAY58-2667 Binding with Human and Bacterial H-NOX Domains.
Nitric oxide donating aspirins: novel drugs for the treatment of saphenous vein graft failure.
YC-1, a nitric oxide-independent activator of soluble guanylate cyclase, inhibits platelet-rich thrombosis in mice.
Toxemia
Atrial natriuretic peptide and sodium azide dependent guanylate cyclase activities in placentas from normal and severely toxemic patients.
Trigeminal Neuralgia
Involvement of the BNP/NPR-A/BKCa pathway in rat trigeminal ganglia following chronic constriction injury.
Tuberculosis
Drug discovery targeting heme-based sensors and their coupled activities.
Tuberculosis, Pulmonary
[Guanylate cyclase from human platelets in pulmonary tuberculosis]
Uremia
Soluble guanylate cyclase stimulator BAY 41-8543 and female sex ameliorate uremic aortic remodeling in a rat model of mild uremia.
Ureteral Obstruction
Impact of biological gender and soluble guanylate cyclase stimulation on renal recovery after relief of unilateral ureteral obstruction.
Stimulation of soluble guanylate cyclase improves renal recovery after relief of unilateral ureteral obstruction.
Unilateral ureteral obstruction increases glomerular soluble guanylyl cyclase activity.
Urethral Obstruction
Reduction of obstruction related bladder overactivity by the guanylyl cyclase modulators BAY 41-2272 and BAY 60-2770 alone or in combination with a phosphodiesterase type 5 inhibitor.
Urinary Bladder, Overactive
The Soluble Guanylyl Cyclase Activator BAY 60-2770 Ameliorates Overactive Bladder in Obese Mice.
Urinary Tract Infections
Urinary nitric oxide synthase activity and cyclic GMP levels are decreased with interstitial cystitis and increased with urinary tract infections.
Urogenital Diseases
Stimulators and activators of soluble guanylate cyclase for urogenital disorders.
Vascular Diseases
Activation of haem-oxidized soluble guanylyl cyclase with BAY 60-2770 in human platelets lead to overstimulation of the cyclic GMP signaling pathway.
Nitric oxide-independent vasodilator rescues heme-oxidized soluble guanylate cyclase from proteasomal degradation.
Oxidant-redox regulation of pulmonary vascular responses to hypoxia and nitric oxide-cGMP signaling.
Prolonged therapy with the soluble guanylyl cyclase activator BAY 60-2770 restores the erectile function in obese mice.
Soluble Guanylate Cyclase Stimulators and Activators: Novel Therapies for Pulmonary Vascular Disease or a Different Method of Increasing cGMP?
Sphingosine-1-phosphate inhibits C-type natriuretic peptide activation of guanylyl cyclase B (GC-B/NPR-B).
Vascular Ring
Disturbances in ex vivo vascular smooth muscle responses following exposure to Pasteurella haemolytica vaccines.
Halothane and isoflurane inhibit endothelium-derived relaxing factor-dependent cyclic guanosine monophosphate accumulation in endothelial cell-vascular smooth muscle co-cultures independent of an effect on guanylyl cyclase activation.
Isoflurane does not vasodilate rat thoracic aortic rings by endothelium-derived relaxing factor or other cyclic GMP-mediated mechanisms.
The Lignan (-)-Cubebin Inhibits Vascular Contraction and Induces Relaxation Via Nitric Oxide Activation in Isolated Rat Aorta.
Vascular System Injuries
Cygnets: in vivo characterization of novel cGMP indicators and in vivo imaging of intracellular cGMP.
Gender-Specific Modulation of the Response to Arterial Injury by Soluble Guanylate Cyclase alpha1.
Vasoplegia
Blocking soluble guanylate cyclase could be the present and future of NO/cGMP inhibition for vasoplegia treatment.
Guanylate cyclase inhibition by methylene blue as an option in the treatment of vasoplegia after a severe burn. A medical hypothesis.
Intraoperative vasoplegia: methylene blue to the rescue!
Methylene blue and vasoplegia: who, when, and how?
Methylene Blue for Vasoplegia When on Cardiopulmonary Bypass During Double-Lung Transplantation.
Methylene blue for vasoplegic syndrome treatment in heart surgery: fifteen years of questions, answers, doubts and certainties.
Methylene blue: potential use of an antique molecule in vasoplegic syndrome during cardiac surgery.
Methylene blue: the drug of choice for catecholamine-refractory vasoplegia after cardiopulmonary bypass?
Role of Methylene Blue in the Maintenance of Postinduction Hemodynamic Status in Patients with Perforation Peritonitis: A Pilot Study.
The Story of Nitric Oxide, Sepsis and Methylene Blue: A Comprehensive Pathophysiologic Review.
[Adult cardiopulmonary bypass in the twentieth century: science, art or empiricism?]
Vasospasm, Intracranial
Alteration of basilar artery rho-kinase and soluble guanylyl cyclase protein expression in a rat model of cerebral vasospasm following subarachnoid hemorrhage.
Ventilator-Induced Lung Injury
Soluble guanylyl cyclase contributes to ventilator-induced lung injury in mice.
Ventricular Dysfunction, Left
Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study.
Ventricular Fibrillation
An endogenous protectant effect of cardiac cyclic GMP against reperfusion-induced ventricular fibrillation in the rat heart.
Virus Diseases
In vitro-in vivo correlation of the drug-drug interaction potential of antiretroviral HIV treatment regimens on CYP1A1 substrate riociguat.
Viral respiratory infection increases alveolar macrophage cytoplasmic motility in rats: role of NO.
Vision Disorders
Spectrum of retGC1 mutations in Leber's congenital amaurosis.
Whooping Cough
Acidification of serotonin-containing secretory vesicles induced by a plasma membrane calcium receptor.
Activation of guanylate cyclase by E. coli heat-stable enterotoxin (STa). Modulation by NAD and pertussis toxin.
Adenosine 5'-triphosphate, phorbol ester, and pertussis toxin effects on atrial natriuretic peptide stimulation of guanylate cyclase in a human renal cell line.
Alterations in inotropy, nitric oxide and cyclic GMP synthesis, protein phosphorylation and ADP-ribosylation in the endotoxin-treated rat myocardium and cardiomyocytes.
Binding of regulatory subunits of cyclic AMP-dependent protein kinase to cyclic CMP agarose.
C-type natriuretic peptide neuromodulates via "clearance" receptors.
Cardiac role of frog ANF: negative inotropism and binding sites in Rana esculenta.
Does cyclic guanosine monophosphate mediate noradrenaline-induced inhibition of islet insulin secretion stimulated by glucose and palmitate?
Failure of pertussis toxin to inhibit activation of guanylate cyclase by the heat-stable enterotoxin of Escherichia coli (STa) in the T84 cell line.
G(i-1)/G(i-2)-dependent signaling by single-transmembrane natriuretic peptide clearance receptor.
G-protein-sensitive guanylyl cyclase activity associated with plasma membranes.
Ghrelin signalling in guinea-pig femoral artery smooth muscle cells.
Guanylin, uroguanylin, and heat-stable euterotoxin activate guanylate cyclase C and/or a pertussis toxin-sensitive G protein in human proximal tubule cells.
Human recombinant chromogranin A-derived vasostatin-1 mimics preconditioning via an adenosine/nitric oxide signaling mechanism.
Novel isoforms of Mel1c melatonin receptors modulating intracellular cyclic guanosine 3',5'-monophosphate levels.
Pancreastatin activates pertussis toxin-sensitive guanylate cyclase and pertussis toxin-insensitive phospholipase C in rat liver membranes.
Pertussis toxin inhibits endothelium-dependent relaxations evoked by fluoride.
Solubilization and reprecipitation from intestinal brush border membranes of a complex containing guanylate cyclase activatable by the heat-stable enterotoxin.
The opposing effects of calmodulin, adenosine 5'-triphosphate, and pertussis toxin on phorbol ester induced inhibition of atrial natriuretic factor stimulated guanylate cyclase in SK-NEP-1 cells.
Transmembrane signalling of atrial natriuretic peptide in rat renal juxtaglomerular cells.
Two opposite signal transducing mechanisms regulate a G-protein-coupled guanylyl cyclase.
Yersinia Infections
[Prostaglandins and cyclic nucleotides in the gastrointestinal form of yersiniosis]